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resumo 
 
 
As células dendríticas plasmacitóides (pDCs) são um subtipo de Células 
Dendríticas que quando estimuladas podem produzir mediadores pro-
inflamatórios e IFNs do tipo I. Estas células desempenham um papel 
importante em doenças autoimunes como o lúpus sistémico eritematoso, uma 
vez que podem ser ativadas por imunocomplexos formados por DNA do 
próprio, que desencadeia uma resposta de IFNs do tipo I através da via de 
sinalização do TLR-9. Aqui, otimizamos a ativação das células CAL-1, uma 
linha celular de pDCs, com imunocomplexos de DNA nuclear ou mitocondrial 
do próprio com o péptido antimicrobiano LL37, em paralelo com a estimulação 
com CpG-A. Descobrimos que elevadas concentrações de LL37 reduzem a 
viabilidade celular das CAL-1. O próprio DNA-LL37 despoletam a expressão de 
IFN-α e IFN-β nas células CAL-1, sem induzir a expressão de TNF-α, tal como 
em pDCs primárias. As concentrações ideais de DNA e LL37 nos complexos 
que levam a uma forte ativação das CAL-1 são 0.2µg/ml e 10µg/ml, 
respetivamente. Também descobrimos que as células CAL-1 estimuladas com 
imunocomplexos de DNA nuclear do próprio, mas não de DNA mitocondrial do 
próprio, foram capazes de secretar a citocina pro-inflamatória IL-1β. A análise 
imunocitoquímica revelou que os endossomas iniciais e o TLR-9 são 
recrutados após ativação por 30-60minutos com imunocomplexos. Assim, este 
trabalho estabele as células CAL-1 como um modelo celular para a ativação de 
com imunocomplexos. 
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abstract 
 
Plasmacytoid dendritic cells (pDCs) are a subset of Dendritic Cells that when 
stimulated can produce pro-inflammatory mediators and type I IFNs. These 
cells play an important role in autoimmune disease such as systemic lupus 
erythematosus, as they can become activated by immune complexes formed 
with self-DNA, which trigger a type I IFN response through the TLR-9 signaling 
pathway. Here, we optimized activation of CAL-1 cells, a human pDC cell line, 
with immunocomplexes of self-nuclear or mitochondrial DNA with the 
antimicrobial peptide LL37. It was found that high concentrations of LL37 led to 
a reduced CAL-1 cell viability.  Self-DNA-LL37 triggered expression of IFN-α 
and IFN-β in CAL-1 cells, without inducing expression of TNF-α, as in primary 
pDCs. The concentrations of DNA and LL37 in the complexes leading to a 
stronger CAL-1 activation were 0.2µg/ml and 10µg/ml, respectively.  We also 
found that CAL-1 cells stimulated with immune complexes with self-nuclear 
DNA, but not self-mitochondrial DNA, were capable of secreting the pro-
inflammatory cytokine IL-1β. Immunocytochemistry analysis revealed that early 
endosomes and TLR-9 were recruited 30-60 minutes upon activation with 
immune complexes. Thus, this work established CAL-1 cells as a cell model for 
pDC activation with immune complexes. 
 
 
	 	
Contents 
	
	
List	of	Figures	...........................................................................................................................................	i	
List	of	Abbreviations	..............................................................................................................................	iii	
List	of	Tables	.........................................................................................................................................	vii	
I.	Introduction	.........................................................................................................................................	1	
Diseases	and	Auto-immunity	..........................................................................................................	4	
Cytokines	produced	by	pDCs	..........................................................................................................	6	
DC	Activation	...................................................................................................................................	8	
Activation	by	self-DNA	immune	complexes	................................................................................	12	
CAL-1	cell	line	...............................................................................................................................	16	
Objectives	.....................................................................................................................................	17	
II.	Materials	&	Methods	.......................................................................................................................	19	
Cell	culture	...................................................................................................................................	20	
Preparation	of	DNA-complexes	...................................................................................................	20	
Cell	stimulation	.............................................................................................................................	22	
Measuring	RNA	levels	by	qPCR	....................................................................................................	23	
Measuring	cytokine	secretion	by	ELISA	.......................................................................................	26	
Analysis	of	complex	recognition	by	Immunofluorescence	..........................................................	27	
Statistical	Analysis	........................................................................................................................	29	
III.	Results	&	Discussion	.......................................................................................................................	31	
Serum	batch	choice	......................................................................................................................	32	
Optimizing	LL37	Concentration	for	CAL-1	stimulation	with	immune	complexes	.......................	36	
Optimizing	DNA	Concentration	for	CAL-1	stimulation	with	immune	complexes	.......................	42	
Co-localization	Analysis	by	IF	.......................................................................................................	49	
IV.	Conclusions	.....................................................................................................................................	55	
V.	Bibliography	.....................................................................................................................................	57	
	
 
	
	
	 	
	 	
	
	
	
	
	 	
	 	
i	
List of Figures 
 
 
Figure	1	-	Cytokine	production	upon	TLR-7/9	induction	of	MYD88–IRF7	and	MYD88–NF-κB	pathways..
..............................................................................................................................................................	11	
	
Figure	2-	Growth	curve	for	cells	grown	in	medium	supplemented	with	different	sera.	Live	cells	were	
counted	after	diluting	in	trypan	blue	for	each	time	point	indicated.	.................................................	32	
	
Figure	3	–	Flow	Cytometry	analysis	of	cell	viability	for	CAL-1	cells.	A	–selection	of	the	area	containing	
events	considered	for	analysis	of	cell	viability	(gating	–	P1	region);	B	–	viable	cells	will	not	stain	for	
propidium	iodide	and	thus	are	located	in	the	gated	area	(R1).	.........................................................	33	
	
Figure	4	–	Expression	of	mRNA	for	IFN-α	(A),	IFN-β	(B)	and	TNF-α	(C)	was	determined	by	RT-qPCR	for	
CAL-1	cells	cultured	in	medium	supplemented	with	different	batches	of	serum	and	stimulated	with	
CpG-A.	GAPDH	was	used	as	a	reference	gene	and	mRNA	expression	was	normalized	against	values	
obtained	for	0	h	of	incubation.	...........................................................................................................	35	
	
Figure	5	–	Evaluation	by	Flow	Cytometry	of	CAL-1	cells	viability	after	6h	of	stimulation	with	IC	with	
different	concentrations	of	LL37.	Plots	show	the	intensity	of	Propidium	iodide	staining	(FL2)	against	
FCS.	The	percentage	of	events	(R6)	represents	the	viable	cells.	A	–	cells	with	no	treatment;	B	–	cells	
treated	with	IC	prepared	with	5µg/ml	of	LL37;	C	–	cells	treated	with	IC	prepared	with	10µg/ml	of	
LL37;	D	–	cells	treated	with	IC	prepared	with	20µg/ml	of	LL37;	E	–	cells	treated	with	IC	prepared	with	
50µg/ml	of	LL37.	..................................................................................................................................	36	
	
Figure	6	–	Percentage	of	viable	cells	after	6h	(A)	and	24h	(B)	of	incubation	with	immune	complexes	
prepared	with	different	LL37	concentrations	 (5,	10,	20	and	50µg/ml).	Data	was	obtained	by	Flow	
Cytometry	upon	Propidium	Iodide	staining.	.......................................................................................	37	
	
Figure	7	–	Expression	of	mRNA	for	IFN-α	(A),	IFN-β	(B)	and	TNF-α	(C)	was	determined	by	RT-qPCR	for	
CAL-1	cells	incubated	with	immune	complexes	prepared	with	different	LL37	concentrations	(5,	10,	
20	and	50µg/ml)	and	stimulated	 in	parallel	with	CpG-A	or	with	self-DNA,	as	controls.	GAPDH	was	
used	as	a	reference	gene	and	mRNA	expression	was	normalized	against	values	obtained	for	0	h	of	
incubation.	Data	are	mean	of	four	independent	experiments,	error	bars	represent	the	SEM.	........	40	
	
Figure	8	–	Protein	secretion	determined	by	ELISA	for	CAL-1	cells	incubated	with	immune	complexes	
prepared	with	different	LL37	concentrations	(5,	10,	20	and	50µg/ml)	and	stimulated	in	parallel	with	
CpG-A	and	only	with	self-DNA.	A	–	IL-1β	secretion;	B	–	IFN-α	secretion;	C	-	TNF-α	secretion	Data	are	
mean	of	five	independent	experiments,	error	bars	represent	the	SEM.	...........................................	41	
	
Figure	9	-	Expression	of	mRNA	for	IFN-α	(A),	IFN-β	(B)	and	TNF-α	(C)	was	determined	by	RT-qPCR	for	
CAL-1	cells	incubated	with	immune	complexes	prepared	with	different	nDNA	concentrations	(1,	0.5	
and	0.2µg/ml)	and	stimulated	in	parallel	with	CpG-A	and	only	with	LL37	and	self-DNA.	GAPDH	was	
used	as	a	reference	gene	and	mRNA	expression	was	normalized	against	values	obtained	for	0	h	of	
incubation.	Data	are	mean	of	four	independent	experiments,	error	bars	represent	the	SEM.	........	45	
	
	
	
	
	
ii	
Figure	10	-	Expression	of	mRNA	for	IFN-α	(A),	IFN-β	(B)	and	TNF-α	(C)	was	determined	by	RT-qPCR	
for	CAL-1	 cells	 incubated	with	 immune	 complexes	prepared	with	 a	 concentration	of	 0.5µg/ml	of	
mtDNA	and	stimulated	in	parallel	with	CpG-A	and	only	with	LL37	and	self-mtDNA	.........................	47	
	
Figure	11	-	Secretion	of	IL-1β	determined	by	ELISA	for	CAL-1	cells	incubated	for	6h	(A)	and	24h	(B)	
with	immune	complexes	prepared	with	different	nDNA	concentrations	(1,	0.5,	0.2µg/ml)	and	mtDNA	
(0.5µg/ml)	or	stimulated	in	parallel	with	CpG-A	or	only	with	LL37	and	self-DNA,	self-mtDNA.		.......	48	
  
	 	
iii	
List of Abbreviations 	
	
AF		 	Alexa	Fluor	
AIM2	 	Absent	in	melanoma	2	
AMP		 	Adenosine	monophosphate	
ANOVA		 	Analysis	of	variance	
AP3		 	Adaptor	protein	3	
APC		 	Antigen	presenting	cell	
BAD-LAMP		 	Brain	 and	 dendritic	 cell-associated	 lysosome-associated	 membrane	
protein	
BDCA	 Blood	dendritic	cell	antigen	
BSA		 	Bovine	serum	albumin	
CCL	 	C-C	motif	chemokine	ligand	
CCR	 	C-C	motif	chemokine	receptor	
CD		 	Cluster	of	differentiation		
cDC		 	Common	dendrictic	cell	
cDNA		 	Complementary	DNA	
CpG	 	Cytosine	 triphosphate	 deoxynucleotide	 —phosphate—Guanine		
triphosphate	deoxynucleotide	
CXCL	 	C-X-C	motif	chemokine	ligand	
CXCR	 	C-X-C	chemokine	receptor	
DAPI		 	4',6-Diamidino-2-Phenylindole	
DC		 	Dendritic	cell	
DHX36		 	DEAH	box	protein	36	
DNA		 	Deoxyribonucleic	acid	
DNase		 	Deoxyribonuclease	
dNTP		 	Deoxynucleotide	
	
	
	
	
iv	
dsDNA		 	double-stranded	deoxyribonucleic	acid	
EEA1		 	Early	endosome	antigen	1	
EGTA		 	Ethylene	glycol-bis(β-aminoethyl	ether)-N,N,N',N'-tetraacetic	acid	
ELISA		 	Enzyme-linked	immunosorbent	assay	
ER		 	Endoplasmic	reticulum	
FBS		 	Fetal	bovine	serum	
FCγR	 	Fc-gamma	receptor	
GAPDH		 	Glyceraldehyde	3-phosphate	dehydrogenase	
GM-CSF		 	Granulocyte-macrophage	colony-stimulating	factor	
hCAP-18		 	Human	cationic	antimicrobial	protein	
HCl		 	Hydrogen	chloride	
HDP		 	Host-defense	peptide	
HEPES		 	4-(2-hydroxyethyl)-1-piperazineethanesulfonic	acid	
HEV		 	High	endothelial	venule	
HLA-DR		 	Human	leukocyte	antigen	D	related	
HMGB-1		 	High-mobility	group	box	1	
HRP		 	Horseradish	peroxidase	
IC		 	Immune	complex	
IFN		 	Interferon	
IFNAR		 	Interferon-α/β	receptor	
Ig		 	Immunoglobulin	
IKK		 	I	kappa	B	kinase	
IL		 	Interleukin	
ILT		 	Ig-like	transcript		
IPC	 Interferon	producing	cell	
IRAK		 	Interleukin-1	receptor-associated	kinase		
	 	
v	
IRF		 	Interferon	regulatory	factor		
LAMP		 	Lysosome-associated	membrane	protein	
LAP		 	LC3-associated	phagocytosis	
LC3		 	Microtubule-associated	protein	1A/1B-light	chain	3	
MAPK		 	Mitogen-activated	protein	kinase	
MDA-5		 	Melanoma	differentiation-associated	protein		
mDC		 	Myeloid	dendritic	cell	
MHC		 	Major	histocompatibility	complex	
mRNA		 	Messenger	RNA	
mtDNA		 	Mitochondrial	DNA	
MyD88		 	Myeloid	differentiation	primary	response	88	
NADPH		 	Nicotinamide	 adenine	 dinucleotide	 phosphate	 (reduced	 form	 of	
NADP+)	
nDNA		 	Nuclear	DNA	
NEAA		 	Non-essential	amino	acid	
NET		 	Neutrophils	release	extracellular	traps	
NF-κB		 	Nuclear	factor	kappa	B	
NK		 	Natural-killer	
NLR		 	Nod-like	receptors	
ODN		 	Oligodeoxyribonucleotide	
OPN		 	Osteopontin	
ORN		 	Oligoribonucleotide	
Ox-mtDNA		 	Oxidized	mtDNA	
PAMP		 	Pathogen-associated	molecular	pattern	
PBS		 	Phosphate	buffered	saline	
pDC		 	Plasmacytoid	dendritic	cell	
	
	
	
	
vi	
PFA		 	Paraformaldehyde	
PI		 	Propidium	Iodide	
RAGE		 	Receptor	for	advanced	glycation	endproducts	
RIG-I		 	Retinoic	acid-inducible	gene	I	
RNA		 	Ribonucleic	acid	
RNase		 	Ribonuclease	
RPMI		 	Roswell	Park	Memorial	Institute	
RT		 	Room	temperature	
RT-qPCR		 	Real-time	polymerase	chain	reaction	
Siglec-H	 	Sialic	acid	binding	Ig-like	lectin	H	
SLE		 	Systemic	lupus	erythematosus	
ssDNA		 	single-stranded	deoxyribonucleic	acid;	
Th		 	T	helper	cell		
TIR		 	Toll/IL-1	receptor	
TLR		 	Toll-like	receptor		
TMB		 	Tetramethylbenzidine	
TNF		 	Tumor	necrosis	factor	
TRAF		 	TNF	receptor	associated	factor	
UNC93B	 	Protein	UNC93	homolog	B1	
WHO		 	World	health	organization	
	  
	 	
vii	
List of Tables  
 
 
Table	1	–	Primer	sequences	for	each	target	gene.	.............................................................................	25	
	
Table	2	-	Concentration	range	for	antibody	concentration	test.	.......................................................	28	
	
Table	3-	Antibody	concentration	for	evaluation	of	TLR-9	and	EEA1	recruitment	of	immunocomplexes	
with	endosomal	internalization.	..........................................................................................................	29	
	
Table	4-	Number	of	cells	after	culture	in	medium	with	10%	sera	from	different	suppliers,	at	different	
time-points	(0h,	24h,	48h,	72h	and	96h)..	..........................................................................................	32	
	
Table	5	-	Percentage	of	viable	cells	for	each	serum	and	in	each	time	point	.....................................	33	
	
Table	6	-	Relative	amount	of	IFN-α,	IFN-β	and	TNF-α	mRNA	expressed	by	CAL-1	stimulated	with	the	
complexes	formed	with	the	indicated	amount	of	LL37,	measured	by	RT-qPCR,	after	6h	of	incubation.
..............................................................................................................................................................	38	
	
Table	7	-	Relative	amount	of	IFN-α,	IFN-β	and	TNF-α	mRNA	expressed	by	CAL-1	stimulated	with	the	
complexes	formed	with	the	indicated	amount	of	nDNA,	measured	by	RT-qPCR,	after	6h	of	incubation.
..............................................................................................................................................................	42	
	
Table	8	–	Relative	amount	of	IFN-α,	IFN-β	and	TNF-α	mRNA	expressed	by	CAL-1	stimulated	with	the	
complexes	 formed	 with	 the	 indicated	 amount	 of	 mtDNA,	 measured	 by	 RT-qPCR,	 after	 6h	 of	
incubation.	...........................................................................................................................................	46	
	
	
	
	
viii	
  
	
	
1	
	
	
	
	
	
	
	
	
	
	
	
	
I.	Introduction
	
	
	
	
	
|	INTRODUCTION	|	
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Plasmacytoid	dendritic	cells	(pDCs)	are	a	subpopulation	of	dendritic	cells	(DCs)	specialized	in	
secretion	of	type	I	interferons	(IFNs)	in	response	to	viruses	(1,2).	DCs	efficiently	link	the	innate	and	
the	 adaptive	 immune	 responses	 (3,4)	 via	 cytokine	 production	 and	 antigen	 presentation,	 being	
sentinels	within	the	body.		As	a	DC	derived	population,	the	cytokines	produced	by	pDCs	include	type	
I	IFNs,	interleukine	(IL)-6	and	Tumor	Necrosis	Factor	(TNF)-α	(5,6).	Activated	pDCs	also	function	as	
antigen	presenting	cells	(APC)	and	have	the	potential	to	prime	and	promote	differentiation	of	T	cells	
into	regulatory	or	inflammatory	effector	cells.	For	that,	they	survey	tissues	to	capture	and	present	
antigens	to	instruct	and	shape	the	adaptive	immune	response	either	to	respond	or	to	be	tolerant	
against	peripheral	antigen	(4,7).	These	cells	have	immunoregulatory	effects	that	are	independent	of	
type	I	IFN	production,	since	they	express	Major	Histocompatibility	Complex	(MHC)	class	II	and	co-
stimulatory	molecules	such	as	CD40,	CD86	(7)	and	CD80,	being	able	to	present	antigens	(4,8).	After	
exposure	to	maturation	stimuli	such	as	Toll-like	receptor	(TLR)	ligands,	pDCs	can	prime	CD8+	T	cells	
and	 CD4+	 T	 cells	 (4,7–9).	 However,	 they	 appear	 to	 be	 much	 less	 potent	 APCs	 compared	 to	
conventional	DCs	(cDCs)	in	stimulating	T	cells	(4,8).	pDCs	do	not	always	stimulate	naive	T	cells	but	
they	 can	 be	 converted	 into	 cDC-like	 cells	 upon	 activation	 and	 function	 as	 APCs	 (10),	 sometimes	
leading	to	tolerance	induction	by	acting	as	immunogenic	cells	(11).	More,	type	I	IFN	can	regulate	the	
function	of	B,	T,	DC	and	natural	killer	(NK)	cells	and	can	also	alter	the	residence	time	of	leukocytes	
within	lymph	nodes	(2,4,12).	
pDCs	 were	 first	 described	 in	 1958	 and	 mentioned	 as	 plasmacytoid	 monocytes	 or	
plasmacytoid	T	cells	(13).		Nowadays,	pDCs	are	recognized	as	a	DC	subset	family	that	develops	from	
hematopoietic	stem	cells	in	bone	marrow	(6,14),	being	relatively	abundant	(1-2%)	(15,16).	They	can	
also	be	found	in	peripheral	blood	in	about	0.2%	to	0.8%,	in	healthy	individuals	(17–19).	Despite	being	
a	DC	family,	pDCs	and	cDCs	share	some	similarities,	but	can	be	very	different	as	well.	DCs	leave	the	
bone	 marrow	 to	 give	 rise	 to	 resident	 and	 migratory	 DCs	 (20,21).	 Unlike	 cDCs,	 following	 their	
development	in	bone	marrow,	pDCs	circulate	through	the	bloodstream	and	reach	T	cell	areas	of	the	
lymph	nodes	mainly	through	high	endothelial	venules	(HEVs),	entering	to	lymph	nodes	directly	from	
the	blood.	Thus,	under	steady	state	conditions,	pDCs	are	found	in	thymus,	in	secondary	lymphoid	
tissues,	and	in	rare	numbers	in	peripheral	tissues	(2,4,8,20).	On	their	surface,	resident	pDCs	express	
low	levels	of	chemotactic	molecules	such	as	CXCR4	that	limits	their	motility,	being	required	for	their	
retention	in	the	bone	marrow	stromal	niche	and	for	their	development	(8,20,22).	Upon	retention,	
pDCs	are	difficult	to	found	in	peripheral	tissues	such	as	skin	and	mucosa,	however,	high	numbers	
have	been	found	in	injured	tissues	of	autoimmune	patients	(19).		
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On	the	surface,	pDCs	express	markers	and	receptors,	that	distinguish	them	from	cDCs	and	
regulates	their	functions	(20).	They	were	first	identified	in	humans	as	CD4+,	CD68+	and	IL-3R+	(IL-3	
receptor	also	known	as	CD123)	plasma-like	cells	(23,24).	It	is	now	known	that	pDC	lack	expression	of	
the	 lineage-associated	markers	 CD3,	 CD19,	 CD14,	 CD16	 and	 the	DC	marker	 CD11c.	 pDCs	 can	be	
distinguished	from	other	blood	cells,	by	their	expression	of	C-type	lectin	BDCA-2	(25),	BDCA-4,	B220	
(4),	and	the	immunoglobulin	superfamily	receptor	immunoglobulin-like	transcript	7	(ILT7)	(26).	They	
also	express	MHC-II,	CD2	(11)	and	ILT3	(8).	pDCs	also	show	distinct	molecular	and	cellular	features	
that	underlie	their	unique	IFN-producing	capacity.	These	include:	prolonged	endosomal	retention	of	
(TLRs)	ligands,	basal	expression	of	interferon	response	factor	7	(IRF7)	(the	master	regulator	of	IFN	
response),	“plasmacytoid”	secretory	morphology,	resembling	antibody-secreting	plasma	cells,	and	
expression	of	specific	surface	receptors	that	modulate	IFN	secretion,	such	as	human	ILT7	and	BDCA-
2,	and	Siglec-H	in	mouse	(15,27,28).	
pDCs	 show	 heterogeneous	 expression	 of	 several	 genes,	 suggesting	 a	 certain	 degree	 of	
developmental	and/or	functional	heterogeneity	(15).	Thus,	pDCs	may	not	represent	a	homogenous	
population,	but	rather	subpopulations	with	distinct	functions	(4).	Accordingly,	CD2	distinguishes	two	
human	pDC	 subsets,	where	CD2hi	 pDCs	 expresses	 lysozyme	and	displays	 cytolytic	 capacity,	while	
CD2low	do	not	(29).	More,	blood-derived	pDCs	can	be	subdivided	into	two	different	subsets	-	pDC1	
and	pDC2.	These	subsets	differ	in	their	phenotype	and	in	their	capacity	to	induce	pro-inflammatory	
or	 regulatory	T	cell	 responses.	pDC1	exhibit	a	more	 immature	phenotype	with	 low	expression	of	
MHC-II	and	null	expression	of	the	co-stimulatory	molecule	CD86,	while	pDC2	have	a	more	mature	
phenotype,	expressing	MCH-II	and	CD86	(4).	In	2011,	a	new	pDC	marker	called	BAD-LAMP	(brain	and	
DC	associated	LAMP-like	molecule)	was	discovered.	LAMP	family	members,	specifically	accumulate	
late	endosomes	and	in	lysosomes.	In	humans,	is	found	in	CD123+BDCA-2+BDCA-4+	pDCs	and	is	mostly	
localized	in	the	ER-Golgi	 intermediate	compartment	and	does	not	display	any	obvious	endosomal	
localization	(30).	
Recent	studies	suggested	a	new	DC	phenotypical	evaluation.	Six	DC	clusters	numbered	DC1	
to	DC6	were	defined	by	single-cell	RNA	sequencing,	where	cluster	DC6	is	related	to	pDCs	and	cluster	
DC5	describes	a	new	DC	subset,	named	AS	DCs.	AS	DCs	seem	to	share	gene	expression	signatures	
with	cDCs	and	pDCs,	but	they	activate	T	cells	more	efficiently	than	pDCs	and	are	functionally	different	
from	pDCs.	For	example,	pDCs	(but	not	AS	DCs)	expressed	genes	associated	with	pathogen	sensing	
and	induction	of	type	I	IFN,	like	IRF7.	Thus,	“purified”	pDCs	were	reclassified	as	the	initially	described	
“natural	interferon	producing	cells	(IPCs)”	with	lower	capacity	to	induce	T	cell	proliferation.	AS	DCs	
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were	found	to	be	identical	to	CD2hi	pDC	phenotype.	AS	DCs	were	also	found	morphological	different	
from	pDCs	(31).	
	
	
Diseases	and	Auto-immunity	
	
pDCs	are	involved	in	several	 immune	diseases.	In	normal	conditions,	self-nucleic	acids	are	
rapidly	 degraded	 in	 the	 extracellular	 environment	 and	 fail	 to	 access	 endosomal	 compartments	
spontaneously	 (32).	However,	 self-DNA	and	 self-RNA	 can	 trigger	 pDC	 activation	when	 aberrantly	
transported	into	TLR-containing	endosomes.	That	being	the	case,	pDCs	are	continuously	activated	
to	produce	type	I	IFNs,	which	drives	disease	onset	(33,34).	
Type	I	IFN	production	by	pDCs	in	response	to	acute	viral	infections	is	usually	limited	in	time	
and	amplitude,	becoming	less	important	later	in	infection	(35).	The	impact	of	pDCs	depends	on	the	
route	of	 infection,	and	 the	 requirement	of	pDCs	 for	antiviral	defense	during	 local	 infections	only	
exists	if	other	defense	mechanisms	are	broken	(36).	However,	chronic	pDC	activation	can	be	seen	in	
the	absence	of	infection	and	may	result	in	autoimmune	diseases.	In	those	cases,	pDCs	can	sense	self-
DNA	 released	 from	dying	 cells	 or	 in	 neutrophil	 extracellular	 traps	 complexed	 to	 an	 antimicrobial	
peptide	 LL37	 in	 autoimmune	 diseases	 (37).	 Here,	 pDCs	 have	 been	 implicated	 in	 pathologies	
characterized	by	a	type	I	IFN	signature,	such	as	systemic	lupus	erythematosus	(SLE),	atherosclerosis,	
and	psoriasis	 (6,8,15,20).	Despite	 the	pathological	 role	of	pDCs	 in	autoimmune	skin	diseases,	 the	
physiological	 importance	of	pDCs	 in	 initiating	 skin	wound	healing	 is	 also	 reported.	 Following	 skin	
injury,	pDC	are	recruited	to	the	site	of	tissue	damage	to	sense	self-nucleic	acids	released	by	dying	
cells	in	combination	with	cathelicidins,	and	to	initiate	tissue	repair	via	TLR-induced	IFN-α	production	
(38).	
	 SLE	 is	 the	 second	 most	 common	 autoimmune	 disease	 characterized	 by	 breakdown	 of	
tolerance	to	nuclear	antigens	and	immunocomplexes	(IC)	deposition	in	tissues	(39).	Those	complexes	
contain	autoantibodies	to	nuclear	‘autoantigens’,	nucleic	acid	and	associated	proteins,	being	formed	
in	 circulation	 and	 then	 deposited	 in	 tissues	 causing	 inflammation	 (40,41).	 SLE	 involves	 multiple	
organs,	such	as	skin	and	blood	vessels	(39).	Patients	have	reduced	numbers	of	circulating	pDCs,	but	
high	 number	 in	 skin	 lesions,	 since	 upon	 activation	 pDCs	 upregulate	 expression	 of	 chemokine	
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receptors	CXCR3	and	CCR7,	which	 traffic	 cells	 to	peripheral	 sites	of	 inflammation	and	 the	 lymph	
nodes,	respectively.	The	hallmark	of	SLE	is	the	increased	level	of	antinuclear	antibodies	present	in	
99%	of	individuals	(33).	SLE	patients	have	also	deficient	B	and	T	cell	regulation,	increased	amounts	
of	circulating	cell	material	and	cytokines	at	serum,	that	contribute	to	the	inflammation.	Furthermore,	
increased	IFN-α	levels	at	the	serum	are	correlated	to	disease	activity	and	severity	(40).	pDCs	infiltrate	
the	skin	and	show	increased	serum	levels	of	 IFN-α/β	(42)	upon	delivery	of	 immune	complexes	to	
endosomal	compartments	via	the	Fc	receptor	FcγRII,	which	promote	activation	of	TLR-9	(17).	 IFN	
induction	 (43)	 can	be	enhanced	by	 the	association	of	HMGB1,	DNA	 (41)	 and	neutrophils	 release	
extracellular	traps	(NETs)	containing	chromatin	DNA,	and	LL37	(39,44).	Nucleic	acids	that	stimulate	
pDCs	in	SLE	may	also	be	derived	from	other	types	of	cellular	death,	such	as	necroptosis	or	pyroptosis,	
as	well	as	from	NADPH	independent	release	of	mitochondrial	DNA	(45).		
Psoriasis	is	another	chronic	inflammatory	skin	disease	that	occurs	in	individuals	with	genetic	
predisposition	and	affects	2-3%	of	the	population	(46).	The	main	feature	of	psoriasis	is	the	abnormal	
activation	 of	 DC	 subsets	 in	 dermal	 compartments,	 leading	 to	 the	 downstream	 T-cell-mediated	
autoimmune	cascade	and	the	excessive	production	of	AMPs	and	proteins	by	keratinocytes	(47).	pDCs	
appears	 to	 have	 a	 central	 role	 in	 this	 process	 since	 are	 present	 in	 lesional	 skin	 as	 the	 result	 of	
inflammatory	 process	 and	 associated	 cell	 damage	 (34,48).	 Then,	 engagement	 of	 TLR-9,	 leads	 to	
chronic	IFN-α	production	by	pDCs,	activating	myeloid	DCs	(37,48).	Subsequently,	T	cells	infiltrate	the	
skin	and	secrete	IFN-γ	and	Th17,	 initiating	an	abnormal	and	typical	keratinocyte	proliferation	and	
epidermal	differentiation	(49).		
Finally,	atherosclerosis	is	a	chronic	cardiovascular	pathology	(20),	being	caused	by	a	chronic	
inflammatory	disease	of	the	arterial	wall,	modulated	by	innate	and	adaptive	immune	responses	(37).	
In	this	disease,	monocytes	acquire	a	phenotype	that	is	consistent	with	inflammatory	macrophages	
(50).	 Besides	 monocytes,	 macrophages	 and	 T	 cells,	 also	 pDCs	 can	 be	 detected	 within	 human	
atherosclerotic	lesions	(51).	pDCs	were	found	to	co-localize	with	T	cells	in	atherosclerotic	plaques,	
supporting	 the	 atherosclerosis	 progression	 by	 production	 of	 IFN-α	 (20).	 pDCs	 activation	 also	
promotes	 unspecific	 amplification	 of	 humoral	 immune	 responses	 to	 antigens	 in	 atherosclerosis,	
specifically	 by	 production	 of	 dsDNA	 antibodies	 in	 early	 atherosclerosis.	 IFN-α	 expression	 prime	
reciprocally	NETs	release	from	neutrophils,	driving	positive	feedback	and	amplification,	supporting	
humoral	 immunity	 (52).	 Due	 to	 the	 NETs	 amplification	 (53),	 triggering	 production	 of	 IFN-α	
production	through	TLR-9-mediated	signaling,	by	pDCs	stimulated	with	selft-DNA-LL37	complexes	
(48).	This	shows	that	pDCs	are	not	only	present	in	lymph	nodes	and	spleen	but	could	also	be	detected	
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in	 atherosclerotic	 lesions,	 and	 it	 seems	 to	 correlate	 with	 plaque	 progression	 in	 human	
atherosclerosis	(37).			
mtDNA	 can	 be	 also	 involved	 in	 atherosclerosis	 by	 neutrophils	 release	 of	mtDNA–protein	
complexes	spontaneously	in	the	absence	of	cell	death	and	membrane	disruption	(54).	LL37	is	present	
in	neutrophils	and	NETs	in	atherosclerotic	lesions	and,	both	nDNA	and	mtDNA	are	too,	allowing	the	
assembly	of	either	LL37-nDNA	and/or	LL37-mtDNA	complexes	(53).	
However,	further	studies	are	needed	to	understand	these	diseases	and	a	cell	line	model	of	
pDCs	will	greatly	facilitate	those	studies.	
	
	
Cytokines	produced	by	pDCs		
	
Upon	 activation,	 pDCs	 secrete	 high	 amounts	 of	 cytokines,	 such	 as	 IFN-α	 and	 IFN-β	 (55),	
inducing	innate	immunity	initiation.	Cells	of	the	innate	immune	system	sense	common	pathogen-
associated	 molecular	 patterns	 (PAMPs),	 characteristic	 of	 pathogens,	 directly	 attack	 invading	
microbes	and	directing	the	adaptive	immune	system	to	mount	a	more	precise	response	(56).	IFNs	
are	a	family	of	cytokines	that	exhibit	a	broad	range	of	properties	beyond	antiviral	action	(57)	and	are	
classified	into	3	types,	type	I	(including	IFN-αs,	-β,	-ω,	-ε)	(58),	type	II	(IFN-γ)	(59)	and	type	III	(IFN-λ1,	
IFN-λ2	and	IFN-λ3)	IFNs	(58,60).	They	are	distinguished	by	the	specificity	of	their	cognate	receptors,	
their	primary	amino	acid	sequence	homology,	genetic	locus,	stimulus	and	producing	cell	type	(57).	
Generally,	 IFNs	are	produced	 in	response	to	both	microbial	and	self-nucleic	acids	detected	 in	the	
phagosome,	endosome	or	cytosol	of	innate	immune	cells.	These	cells,	once	activated,	induce	a	family	
of	IFN	specific	transcription	factors	known	as	interferon	response	factors	(IRFs)	(56).	The	regulation	
and	production	of	IFNs	seem	to	be	linked	to	which	IRFs	are	being	expressed.	IRF	1,	3,	5	and	7	appear	
to	be	particularly	important	in	the	induction	of	IFN-α	gene	expression	(61),	whereas	upon	receptor	
activation,	IRF3	is	important	in	the	induction	of	IFN-β	gene	expression,	together	with	NF-κB,	which	
is	not	involved	in	IFN-α	gene	expression	(61).	
Type	 I	 IFNs	were	 initially	described	as	 important	 for	anti-viral	defense	 (56).	Nevertheless,	
type	I	IFNs	are	believed	to	be	central	for	pathogenesis	(41)	and	considered	to	have	pleiotropic	effects	
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on	 cells,	 as	 they	 can	 induce	 an	 antiviral	 state,	 inhibit	 cell	 proliferation,	 modulate	 cell	 fate	
(survival/apoptosis),	 differentiation	 and	 migration.	 Their	 effects	 can	 be	 local,	 at	 the	 site	 of	
production,	or	systemic	(57).	All	type	I	IFNs	signal	through	the	same	receptor,	composed	of	IFNAR1	
and	IFNAR2	(62),	and	it	is	notable	that	type	I	IFNs	are	rarely	produced	singly.	The	IFNAR1	chain	of	
the	receptor	is	considered	the	‘‘signal	transducing	chain’’	binding	a	particular	IFN-α	subtype	and	IFN-
β,	whereas	the	IFNAR2	chain	is	the	high	affinity	binding	chain	(63,64).	
The	 amplitude	 of	 IFN	 signalling	must	 be	 tightly	 regulated	 to	 prevent	 a	 harmful	 immune	
response.	For	example,	type	I	 IFN	production	is	negatively	regulated	by	surface	receptors	such	as	
BDCA-2	and	ILT7,	in	human	pDCs,	which	suppress	the	ability	of	pDCs	to	produce	type	I	IFN	in	response	
to	TLR	ligands	(65).	Additionally,	the	capacity	of	pDCs	to	produce	very	high	levels	of	type	I	IFNs	may	
be	linked	to	their	constitutive	IRF7	expression,	which	in	other	cells	is	usually	low	and	must	be	primed	
by	an	initial	burst	of	IFN-β	before	optimal	levels	of	other	type	I	IFNs	are	produced	(66).	
Besides	producing	type	I	IFNs,	pDCs	can	also	secrete	other	pro-inflammatory	cytokines	such	
as	IL-6,	TNF-α,	and	chemokines,	including	CXC-chemokine	ligand	8	(CXCL8),	CXCL10,	CC	chemokine	
ligand	3	(CCL3)	and	CCL4	(8).		Here,	IL-6	and	TNF-α	regulate	T,	B,	NK	cell	and	cDCs	responses,	together	
with	IFN-α	and	IFN-β	(28).	By	producing	IL-6	and	type	I	IFNs,	pDCs	can	also	induce	the	differentiation	
of	 B	 cells	 into	 immunoglobulin-secreting	 plasma	 cells	 and	 instruct	 plasma	 cells	 to	 preferentially	
secrete	 IgG	 rather	 than	 IgM	 (52).	More,	 type	 I	 IFNs	 and	 IL-12	 promote	multiple	 T	 cell	 functions	
including	long-term	T-cell	survival,	memory,	CD8+	T-cell	cytolytic	activity	(67),	IFN-γ	production	and	
increase	NK	cell-mediated	cytotoxicity	 (68).	By	producing	chemokines,	pDCs	can	attract	activated	
CD4+	and	CD8+	T	cells	 to	sites	of	 infection	(69).	Here,	pDCs	have	the	potential	 to	 impact	multiple	
aspects	of	innate	and	adaptive	immune	responses	to	viruses	(11).		Also,	accumulating	evidence	from	
previous	studies	suggested	that	TNF-α	play	an	important	role	in	pathogenesis	(70),	being	produced	
by	Myd88-NF-кB	pathway	(71).	However,	this	TNF-α	expression	is	upregulated	by	TLR-4	(70),	that	is	
not	expressed	on	pDCs	(72).	Accordantly,	pDCs	do	not	express	TNF-α	upon	activation	(73).		
As	with	type	I	IFN,	certain	cytokines	are	important	mediators	regulating	the	immune	response.	
IL-1β	 is	 one	 of	 the	 most	 relevant	 regulating	 cytokines,	 since	 it	 can	 mediate	 a	 wide	 range	 of	
proinflammatory	activities	in	several	human	diseases,	playing	several	functions	in	immune	defense.	
IL-1β	is	transcribed	as	an	immature	pro-peptide,	which	must	be	proteolyticaly	activated	by	caspase-
1	(74,75).	Caspase-1	is	triggered	after	formation	of	the	so	called	‘inflammasomes’.	Inflammasomes	
are	 formed	 upon	 danger-associated	 or	 PAMP	 recognition	 (76)	 and	 are	 defined	 as	 multiprotein	
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complexes	that	recruits	the	assemble	of	Nod-like	receptors	(NLRs).	This	assemble	turn	them	able	to	
bind	 the	 adaptor	 apoptosis-associated	 protein,	 inducing	 the	 autocleavage	 of	 caspase-1	 and	
production	 of	 IL-1-like	 cytokines.	 This	 leads	 to	 high	 concentrations	 of	 proinflammatory	
inflammasome-related	cytokine,	such	as	IL-1α/β	and	IL-18	(74,77).		
Type	 I	 IFN	 possess	 strong	 inflammatory	 properties	 contributing	 to	 the	 inflammasome-
dependent	caspase-1	activation,	 leading	 to	proinflammatory	pyroptotic	cell	death.	Pyropoptosisis	
associated	with	production	of	IL-1β	and	IL-18,	increases	the	proinflammatory	microenvironment	in	
infected	and	wounded	tissues	(78).	These	cytokines	may	be	secreted	by	immune	cells	such	as	DCs	
(77).	As	with	other	 immune	responses,	uncontrolled	 IL-1β	production	may	cause	damage	to	host	
tissues	 and	exacerbate	pathologies	with	 an	 inflammatory	 component	 (74),	 such	as	psoriasis	 that	
increases	the	caspase-1	activity,	suggesting	inflammasome	activation	(79).		
TLR	recognition	of	ligands	culminates	in	downstream	secretion	of	chemokines	and	cytokines,	
such	 as	 IL-1β	 pro-form	 (74).	 Additionally,	 a	 synergy	 seems	 to	 exist	 between	 type	 I	 IFN	 and	 TNF	
pathways,	 with	 a	 reciprocal	 regulation,	 since	 the	 lack	 of	 IFN-α/β	 signaling	 did	 not	 reduce	 the	
induction	of	TNF-α,	IL-1α	or	IL-1β.	Also,	MyD88	requirement	in	the	induction	of	all	proinflammatory	
genes	demonstrates	an	important	role	for	signaling	through	TLRs	(80).		
pDCs	seem	to	be	linked	with	IL-1β	induction	since	their	depletion	affect	the	production	of	TNF-
α,	IL-1α,	and	IL-1β	mRNA	(80),	whereas	their	presence	promotes	IL-1β	release,	indirectly	helping	to	
contain	infections	(81).		
	
	
DC	Activation	
	
Production	 of	 type	 I	 IFNs	 by	 pDCs	 occurs	 after	 TLR-7/-9	 triggering	 (28)	 augmenting	 the	
expression	 of	 antiviral	molecules	 and	 promoting	 apoptosis	 of	 virally	 infected	 cells	 (82).	 This	 IFN	
secretion	by	pDCs	is	recognized	by	rapid	kinetics,	high	level	(up	to	1000-fold	higher	than	most	cells)	
and	appears	critical	for	innate	immune	responses	against	many	viruses	(1).	
TLRs	are	a	set	of	type	I	transmembrane	proteins	evolutionarily	conserved	among	insects	and	
vertebrates,	of	which	at	least	10	members	have	been	identified	in	humans	(5).	They	are	membrane-
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spanning	molecules	that	contain	an	ectodomain	of	leucine-rich	repeats,	a	transmembrane	domain	
and	a	cytoplasmic	domain	known	as	TIR	(Toll/IL-1	receptor)	domain	(28).	
Dendritic	cells	sense	viral	infections	through	a	subset	of	nucleic	acid–recognizing	TLRs,	with	
human	pDCs	selectively	expressing	TLR-7	and	TLR-9	(34).	pDCs	TLR-7	and	TLR-9	are	expressed	within	
endosomal	 compartments	 and	 detect	 nucleic	 acids	 derived	 from	 viruses,	 bacteria,	 or	 dead	 cells.	
Engagement	of	TLR-7	and	-9	with	their	 ligands	(RNA	or	DNA,	respectively)	 triggers	a	downstream	
signaling	cascade	(28).	TLR-9	senses	double-stranded	(ds)	DNA	viral	genomes	rich	in	unmethylated	
CpG	 sequences	 or	 phosphodiester	 backbone	 in	 natural	 DNA,	 as	 well	 as	 synthetic	 CpG	
oligodeoxyribonucleotides	 (CpG	ODN).	 TLR-7	 detects	 viral	 single-stranded	 (ss)	 RNA	 and	 synthetic	
oligoribonucleotides	 (ORN),	 that	 includes	 uridine-rich	 ssRNA,	 synthetic	 imidazoquinolines	 and	
guanosine	analogues	(11,17,34).	
TLR-9	 and	 TLR-7	 are	 synthesized	 in	 the	 endoplasmic	 reticulum	 and	 transported	 into	
endosomes,	 where	 TLR-9	 is	 converted	 into	 an	 active	 form	 by	 proteolytic	 cleavage	 (83).	
Compartmentalization	of	TLR-9	facilitates	the	interaction	with	foreign	DNA	and	decreases	the	risk	of	
contact	with	self-DNA	which	can	ultimately	lead	to	the	development	of	autoimmune	diseases	(32).	
Thus,	the	endosomal	location	of	TLR-9	prevents	immune	responses	to	extracellular	self-DNA	because	
this	DNA	fails	to	enter	the	cells	spontaneously	(5).	The	delivery	of	viral	nucleic	acids	into	intracellular	
endosomes	 containing	 active	 TLR-9	 and	 TLR-7	 requires	 a	 tight	 spatiotemporal	 regulation	 of	
membrane	 trafficking	 (84).	 Such	 regulation	 can	be	observed	 for	 TLR-7	 and	TLR-9	upon	microbial	
activation,	 as	 they	 travel	 to	 the	 endosomes	 to	 become	 proteolytically	 activated	 (17,28,30).	
Spatiotemporal	 regulation	 is	 critical	 for	a	high-level	 IFN	 induction	 in	 response	 to	TLR-9	activation	
(84),	 given	 that	 the	 recognition	of	 nucleic	 acids	by	endosomal	 TLRs	 requires	 the	maturation	and	
acidification	 of	 the	 endosomes	 (19).	 For	 this,	 the	 IFN-inducing	 TLR-9	 ligand	 is	 retained	 for	 long	
periods	in	the	endosomal	vesicles	of	pDCs	(84).	There	are	several	chaperone	proteins	involved	in	TLR	
egress	 control	 from	 ER.	 For	 example,	 the	multi-transmembrane	 endoplasmic	 reticulum	 resident	
protein	UNC93B.	This	protein	specifically	interacts	with	the	transmembrane	domains	of	TLR-7	and	
TLR-9	 and	 controls	 their	 delivery	 to	 the	 endosomes	 upon	 activation	 (17,28,30).	 Here,	 UNC93B	
delivers	TLR-7/-9	from	the	endoplasmic	reticulum	to	endolysosomes	where	the	ectodomains	of	TLR-
7/-9	are	cleaved	by	cathepsins	and	asparagine	endopeptidase	to	generate	functional	TLRs	for	ligand	
recognition	(85).	
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MyD88	serves	as	a	key	adaptor	molecule	that	functions	to	recruit	IL-1-receptor	associated	
kinases	(IRAKs)	to	almost	all	TLRs	and	to	the	IL-1	receptor	(86).		MyD88	binding	to	TLRs	then	initiates	
a	multiple	signaling	pathway,	such	as	NF-κB,	mitogen-activated	protein	kinases	(MAPKs)	and	IRFs,	
and	initiates	the	production	of	cytokines,	chemokines	and	co-stimulatory	molecules	(28)	(Figure	1).	
This	 response	 is	dependent	on	cell	 type.	 In	pDCs,	MyD88-dependent	pathways	mostly	 induce	an	
enormous	amount	of	type	I	IFNs	or	proinflammatory	responses,	such	as	production	of	TNF-α,	IL-6	
and	IL-12	(60).	Here,	in	the	first	6hours	following	TLR-7/-9	activation,	pDC	devote	up	to	60%	of	their	
transcriptome	to	expression	of	type	I	and	type	III	IFN	genes.	Such	capacity	requires	specific	cellular	
and	molecular	mechanisms.	The	rapid	IFN-α/β	production	is	mediated	by	constitutive	expression	of	
IRF7	(87).	The	activation	of	this	pathway	causes	large	pre-made	quantities	of	IRF7	(which	is	unique	
for	this	cell	type)	to	dimerize	(88).	(89)	(90)	(43)	(91)	(17)	(92)	(80,93,94)	(95,96)	(28,97)	(8)	
There	are	 some	 synthetic	ODNs	expressing	CpG	motifs	 that	 are	able	 to	 trigger	 an	 innate	
immune	 response	 via	 TLR-9	 (98).	 Activation	 of	 human	 pDCs	 with	 CpG	 ODNs	 is	 well-established	
(99,100),	being	the	major	effectors	of	this	response	(73).	CpG	ODNs	can	be	divided	in	two	structurally	
distinct	classes	that	activate	pDCs:	CpG-A	(known	as	“D”	ODNs)	that	induce	the	secretion	of	IFN-α	by	
pDCs	 that	 then	activate	NK	cells,	which	stimulate	 IFN-γ	production;	and	CpG-B	 (also	 referred	“K”	
ODNs),	 that	 triggers	 the	production	of	 TNF-α	and	 IL-6,	 inducing	B-cell	 proliferation	and	antibody	
production	(98,101).	These	studies	suggest	that	pDCs	may	have	developed	two	different	signaling	
mechanisms	to	respond	to	different	types	of	CpG	ODN.	CpG	binds	to	the	cell	surface,	enters	the	cell	
by	means	of	clathrin-dependent	pathways	and	 is	recognized	by	TLR-9	 located	 in	the	endoplasmic	
reticulum	and	endosomal	compartments.	TLR-9	responds	to	different	types	of	ODNs,	which	is	in	part	
dependent	 on	 sequence	 motifs	 and	 secondary	 structures	 (102).	 Here,	 CpG-B	 are	 linear	 single-
stranded	 polynucleotides	 that	 express	 multiple	 unmethylated	 CpG	 motifs,	 triggering	 a	 NF-kB-
dependent	proinflammatory	response	characterized	by	the	production	of	IL-6	and	TNF-α	by	pDCs.	In	
contrast,	CpG-A	form	complex	stem	loop	structures	and	have	a	poly-G	tail	that	leads	them	to	form	
G-tetrads,	which	stimulate	pDCs	to	produce	IFN-α/β	rather	than	TNF-α,	an	effect	that	is	amplified	
though	an	autocrine	feedback	loop	(28).	Here,	synthetic	oligodeoxynucleotides	expressing	such	CpG	
motifs	mimic	the	ability	of	bacterial	DNA	to	stimulate	pDCs	(18).		
TLRs	are	established	as	the	main	innate	receptors	in	pDC	activation.	However,	studies	began	
to	exploit	 the	 impact	of	cytosolic	nucleic	acid	sensors	on	type	 I	 IFN	or	pro-inflammatory	cytokine	
production	by	pDCs.	Recently	it	was	shown	that	several	CpG	ODNs	can	also	link	cytosolic	receptors,	
mediating	immune	responses.	CpG-A	oligonucleotides	bind	selectively	to	the	(DExD/H)-box	helicase	
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DHX36,	 associated	with	 translocation	 of	 IRF7	 to	 the	 nucleus	 and	 type	 I	 IFN	 production	 in	 pDCs,	
whereas	CpG-B	oligonucleotides	are	bound	by	DHX9,	resulting	in	NF-κB	activation	and	secretion	of	
pro-inflammatory	cytokines	(103).	Similarly,	pDCs	also	express	two	cytosolic	sensors	for	viral	RNA,	
namely	RIG-I	and	MDA5		(104).	Uptake	and	recognition	of	viral	nucleic	acids	by	pDCs	may	probably	
occur	independently	of	viral	infection	mechanisms.	Here,	viruses	and	endogenous	nucleic	acids	can	
enter	pDCs	through	Fc	receptors	when	bound	by	antibodies	during	an	immune	response,	specifically	
activating	the	Fc	receptor	FcγRIIA	(40).	
	
Figure	1	-	Cytokine	production	upon	TLR-7/9	induction	of	MYD88–IRF7	and	MYD88–NF-κB	pathways.	Trafficking	of	TLR-9	to	the	
subcellular	compartment	for	 type	I	IFN	production	is	dependent	on	adaptor	protein	3	 (AP3)	(89).	However,	TLR-9	mediated	
recognition	of	large	DNA-containing	immune	complexes	is	independent	of	AP3	and	requires	the	convergence	of	phagocytic	and	
autophagic	pathways.	This	process	is	called	microtubule-associated	protein	1A/1B	light	chain	3	(LC3)-associated	phagocytosis	
(LAP)	and	involves	autophagy-related	proteins	but	not	the	conventional	autophagic	pre-initiation	complex	(90).	In	the	absence	
of	PAMPs,	TLR-9	resides	in	the	endoplasmic	reticulum	of	resting	pDCs	and	is	only	translocated	to	the	endosomal	compartment	
on	exposure	to	TLR	agonists.	TLR	linkage	with	the	early	endosomal/lysosome-related	compartment	will	preferentially	lead	to	
IFN	 production,	 whereas	 late	 endosomal/lysosomal	 engagement	 induces	 pro-inflammatory	 cytokine	 production	 and	
maturation	(89).		Thus,	production	of	type	I	IFN	or	pro-inflammatory	cytokines	depends	on	the	type	of	compartment	in	which	
these	TLRs	encounter	their	ligands	(43).	After	ligand	engagement,	activation	of	TLR-9	by	nucleic	acids	leads	to	the	recruitment	
of	the	adaptor	protein	MyD88	and	to	the	assembly	of	a	multiprotein	signal	transduction	complex	in	the	cytoplasm	(91).	The	
signaling	cascade	downstream	forms	a	multiprotein	signal	transduction	complex	that	contain	IL-1	receptor-associated	kinase	
4	 (IRAK4),	 TNF	 receptor-associated	 factor	 6	 (TRAF6),	 Bruton’s	 tyrosine	 kinase	 (BTK)	 and	 IRF7	 (17).	 Here,	 IRF7	 is	 activated	
through	ubiquitylation	by	 the	ubiquitin	E3	 ligase	activity	of	TRAF6	and	phosphorylated	by	 IRAK4	(92).	Phosphorylated	 IRF7	
interacts	with	TRAF3,	 IB	kinase	(IKK),	IRAK1,	osteopontin	(OPN)	and	potentially	phosphatidylinositide	3-kinase	(PI3K),	and	is	
then	translocated	into	the	nucleus	where	it	initiates	the	transcription	of	type	 I	IFN	genes	(80,93,94).	Simultaneously,	TRAF6	
complex	may	ubiquitylate	the	protein	kinase	transforming	growth	factor-β	(TGF-β)-activated	kinase	1	(TAK1),	(95,96)	a	signal	
transducer	that	activates	NF-κB	and	MAPKs	for	the	induction	of	transcription	of	pro-inflammatory	cytokines,	chemokines	and	
co-stimulatory	molecules	(28,97).	Thus,	activation	of	these	TLRs	can	mediate	two	different	pathways:	MYD88–IRF7	pathway	
and	MYD88–NF-κB	pathway	(8).	
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Activation	by	self-DNA	immune	complexes	
	
pDCs	are	activated	by	DNA	of	viruses	and	other	TLR-9	ligands,	such	as	CpG-A.	However,	not	
only	viral	nucleic	acids	activate	pDCs	(19),	but	self-DNA	somehow	also	access	the	TLR-9-containing	
intracellular	compartments,	triggering	a	type	I	IFN	response.	pDCs	normally	do	not	respond	to	the	
host-derived	 self-DNA	 that	 typically	 is	 released	 into	 the	 extracellular	 environment	by	dying	 cells.	
However,	 it	 was	 recently	 shown	 that	 self-nucleic	 acids	 can	 form	 complexes	 with	 a	 cationic	
antimicrobial	peptide	LL37	(48).	LL37	is	produced	in	skin	wounds	and	overexpressed	in	psoriasis,	a	
common	autoimmune	disease	of	the	skin	(5).	Antimicrobial	peptides	(AMPs),	such	as	LL37,	are	found	
both	in	nonvertebrates	and	vertebrates,	allowing	efficient	lysis	of	the	invading	microbes	(89).	LL37	
is	also	considered	as	a	Host-defense	peptide	(HDP)	(105).	AMPs	are	one	of	the	defense	mechanisms	
of	 eukaryotic	 cells	 against	 bacteria,	 protozoa,	 fungi,	 and	 viruses,	 and	 are	 produced	 at	 damaged	
epithelial	surfaces,	preventing	microbial	invasion	by	directly	killing	pathogens	through	their	cationic	
and	amphipathic	structure,	interacting	and	disrupting	microbial	membranes,	which	typically	contain	
negative	charges	(106).	The	main	AMPs	in	human	skin	are	the	defensins,	which	comprise	multiple	
cysteine-rich	beta-sheet	peptides,	and	the	cathelicidins,	a	peptide	family	with	only	one	member	with	
α-helical	structure.		LL37	is	included	in	cathelicidins,	playing	a	major	role	in	initiation	of	inflammation	
in	response	to	skin	damage	by	infection	or	injury	(107).	High	LL37	concentrations	affects	cell	viability,	
and	thus	the	function	of	LL37	requires	tight	regulation	(108).	The	antibacterial	activity	is	regulated	
by	environmental	changes	in	osmolarity	or	pH,	which	relates	to	the	fact	that	LL37	adopts	an	α-helical	
oligomeric	conformation	in	its	active	state	(109).	In	DCs,	LL37	was	found	to	profoundly	influence	the	
exact	course	of	their	maturation	process,	a	process	which	forms	the	borderline	between	innate	and	
adaptive	immunity	(110).	LL37	owes	its	name	to	its	37-amino	acid	length,	initiated	by	two	leading	
leucine	 residues,	 not	 containing	 any	 cysteine	 residues.	 This	 is	 the	 only	 known	 human	 cathelin-
associated	antimicrobial	peptide	and	belongs	to	the	class	of	α-helical	AMPs	(110,111).	This	peptide	
has	been	shown	to	be	secreted	by	multiple	cell	types	(111),		being	first	described	in	leukocytes	and	
testis,	but	being	 later	 found	 in	a	 large	variety	of	cells,	 tissues	and	body	 fluids.	Thus,	 LL37	and	 its	
precursor	hCAP18,	can	be	found	at	different	concentrations	in	very	different	cell	and	tissue	types	
and	body	fluids	(110).	
LL37	is	present	in	the	dermal	compartment	in	close	association	with	high	numbers	of	pDCs	
and	is	produced	and	secreted	by	keratinocytes	and	neutrophils	as	part	of	hCAP18	and	cleaved	into	
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the	 mature	 (biological	 active)	 37-amino-acid	 AMP	 by	 serine	 proteases.	 However,	 LL37	 is	 not	
expressed	by	healthy	skin	keratinocytes,	but	only	following	skin	injury	(48).	
Crucially,	 LL37	mediates	 pDCs	 activation	 by	 converting	 self-DNA	 into	 structures	 that	 are	
sequestered	in	endosomal	compartments	where	they	trigger	type	I	 IFN	production	through	TLR-9	
(48),	as	shown	in	autoimmune	diseases	(37).	LL37	is	able	to	form	complexes	with	self-DNA,	enabling	
efficient	 internalization	 of	DNA	 to	mammalian	 cells,	 by	 binding	DNA	 via	 nonspecific	 electrostatic	
interactions	(109).	Within	these	complexes,	LL37	protects	DNA	from	endonucleases	and	facilitates	
the	delivery	of	nucleic	acids	into	the	endosomal	and	cytosolic	compartments	(109,112).	The	degree	
of	 IFN-α	 production	 may	 be	 modulated	 by	 the	 efficiency	 of	 endosomal	 access.	 Also,	
immunocomplexes	 can	 cross-link	 multiple	 TLR-9	 receptors,	 leading	 to	 receptor	 recruitment	 and	
amplification	of	the	immune	response	(56).		
As	a	complex,	LL37	and	DNA	together	can	trigger	an	over	and	continuous	IFN	response	in	
pDCs,	 leading	 to	 the	 initiation	 and	 maintenance	 of	 autoimmune	 skin	 inflammation	 (5).	 This	
phenomenon	involves	three	distinct	steps.	First,	LL-37	binds	to	DNA	fragments	to	form	aggregated	
and	condensed	structures	that	are	resistant	to	extracellular	degradation.	Second,	LL-37	promotes	
DNA	translocation	into	the	endocytic	compartment	of	pDCs,	thereby	bypassing	a	safety	mechanism	
for	discrimination	of	viral/microbial	from	self-nucleic-acids	provided	by	the	intracellular	localization	
of	 TLR-9.	 This	 process	 involves	 the	 attachment	 of	 LL-37	 to	 proteoglycans	 in	 the	 cell	 membrane	
followed	 by	 lipid-raft	 mediated	 endocytosis,	 an	 entry	 mechanism	 described	 for	 certain	 viruses.	
Finally,	LL-37	retains	the	DNA	complex	in	early	endocytic	compartments	of	pDCs,	perhaps	modifying	
them	in	the	process,	to	specifically	sustain	the	TLR-9-mediated	IFN	response.	Thereby,	LL-37	breaks	
innate	 tolerance	 to	 self-DNA	 and,	 in	 a	 similar	 way	 to	 viral	 responses,	 elicits	 a	 rapid	 and	 robust	
induction	of	IFNs	that	initiate	innate	and	adaptive	immunity,	allowing	a	selective	and	sustained	IFN	
induction	via	TLR-9/MyD88/IRF7	signaling	(5,48).		
The	immunogenicity	of	LL-37	is	entirely	dependent	on	its	positive	charges	clustered	on	one	
side	of	the	molecule	that	neutralizes	the	negatively	charged	phosphate	backbone	of	DNA,	leading	to	
DNA	 condensation	 to	 small	 particles	 that	 are	 protected	 from	 nuclease	 degradation.	 These	 DNA	
particles	acquire	a	slight	positive	charge	as	some	cationic	residues	of	the	complexed	peptide	remain	
exposed,	allowing	interaction	of	the	complex	with	heparin	sulfate	proteoglycans	in	cell	membranes,	
followed	by	internalization	via	endocytosis	(113).	New	evidences	suggest	that	the	inter-DNA	spacing	
is	an	important	criterion	for	pDC	activation	in	these	complexes,	since	LL-37–DNA	complexes	seem	to	
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have	 a	 columnar	 structure	 with	 a	 relatively	 large	 inter-DNA	 spacing	 (a=3.40	 nm)	 (56).	 Recent	
evidence	 suggests	 that	 HMGB1,	 a	 DNA-binding	 factor	 released	 by	 dying	 cells,	 can	 bind	 only	
multimeric	aggregates.	HMGB1	may	bind	LL-37-self-DNA	complex,	promoting	prolonged	association	
with	TLR-9	in	early	endosomes	by	engaging	the	receptor	of	advanced	glycation	endproducts	(RAGE).	
The	complex	is	protected	from	nuclease	degradation	and	delivered	to	endocytic	compartments	of	
pDCs	 to	TLR-9	 retention	within	early	endosome,	 leading	 to	a	 robust	 induction	of	 type	 I	 IFNs	 that	
initiate	an	antiviral-like	immune	response	(56).	More,	in	pDCs	LL-37-DNA	complexes	are	contained	
within	the	early	endosomes	(112)	and	their	uptake	is	a	saturable	time-	and	temperature-dependent	
process	(no	DNA	uptake	at	4	°C),	which	is	consistent	with	an	endocytotic	uptake	mechanism	(109).	
In	context	of	SLE,	HMGB1	is	released	from	cells	undergoing	necrosis	or	is	secreted	from	cells	
after	 inflammatory	 cytokine	 stimulation	 (114).	 In	 addition,	 in	 SLE,	 self-DNA–LL37	 complexes	 are	
released	 by	 dying	 neutrophils	 undergoing	 NETosis,	 a	 cell	 death	 process	 in	 which	 activated	
neutrophils	extrude	nuclear	DNA	into	the	extracellular	space	in	the	form	of	NETs.	NETs	may	serve	as	
a	source	of	autoantigen	and	LL37,	promoting	aggregation	and	stimulation	of	IFN-α	by	pDCs	(115).	
This	 raises	 the	possibility	 that	HMGB1	may	contribute	to	autoimmune	disorders	characterized	by	
type	 I	 IFNs,	 through	 a	 mechanism	 dependent	 on	 MyD88–TLR-9	 pathway	 and	 RAGE.	 Moreover,	
HMGB1	 seem	 to	 be	 present	 in	 immune	 complexes	 with	 DNA	 and	 to	 trigger	 type	 I	 interferon	
production	after	RAGE	engagement	(41).	
IL-1β	also	seem	to	be	related	with	autoimmune	diseases,	such	as	psoriasis	(79),	where	a	role	
for	LL37	seem	to	exist.	In	fact,	LL37	peptide	may	enhance	IL-1β	induction	by	some	cell	types	(5,19).		
LL37	can	regulate	the	release	of	IL-1β	secretion	stimulus	in	monocytes,	linking	the	innate	and	the	
adaptive	 immune	 system	 (75)	 and	 seems	 to	 induce	 inflammasome	 formation,	 in	 a	 process	
independent	of	TLRs	and	IRFs	(116).	The	self-DNA	present	in	keratinocytes	in	psoriatic	lesions	was	
also	found	to	have	pro-inflammatory	response	induction	and	to	triggers	IL-1β	secretion	through	the	
AIM2	 inflammasome.	 However,	 binding	 of	 LL37	 to	 self-DNA	 neutralizes	 this	 DNA-mediated	
inflammation.	Therefore,	LL37	shows	opposite	roles	in	skin	inflammation	in	psoriasis	(76).	Thus,	LL37	
can	also	block	 inflammasome	formation	by	binding	to	cytosolic	DNA	(105).	However,	not	much	is	
known	of	how	the	activity	of	cytosolic	LL37	is	regulated	and	neither	about	the	role	of	CAL-1	cells	in	
inflammasome,	leading	space	for	further	investigation.	
Self-RNA–LL37	complexes	also	trigger	the	direct	activation	of	mDCs	to	secrete	TNF-α	and	IL-
6	and	differentiate	into	mature	DCs.	Again,	the	formation	of	the	complexes	is	driven	by	the	cationic	
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residues	of	LL37	and	the	anionic	phosphate	backbone	of	RNA,	similar	to	the	phenomenon	described	
for	DNA.	Thus,	LL37	allows	the	association	of	RNA	with	cellular	membranes	and	the	transport	across	
these	membranes	 into	endocytic	compartments	 (34).	Other	molecules	have	similar	effects,	being	
able	to	condense	self-DNA	into	particles	capable	of	being	endocytosed	by	pDCs,	leading	to	activation	
of	TLR9.		Some	of	them	are	hBD2,	hBD3,	and	lysozyme,	and,	like	LL37,	are	found	in	skin	injury	and	
found	to	have	inducing	IFN	production	skills	(113).	
Mitochondria	 have	 circular	 DNA	 genome	 containing	 unmethylated	 CpG	
oligodeoxynucleotide	(ODN)	sequences.	Mitochondrial	DNA	(mtDNA)	molecules	released	by	injured	
or	even	living	cells	are	sensed	as	danger	signals,	initiating	immune	responses	(117).		Recently,	it	was	
shown	that	mtDNA	and	LL37	are	also	involved	in	atherosclerosis,	as	high	amounts	of	LL37-mtDNA	
complex	were	found	in	atherosclerotic	plasma	and	plaques.	LL37-mtDNA	complex	was	also	found	to	
cause	inflammation	by	activation	of	TLR-9-mediated	inflammatory	responses	(53).	LL-37	has	been	
identified	residing	in	neutrophil	and	NETs	in	atherosclerotic	lesions	and,	both	nDNA	and	mtDNA	are	
present	in	NETs	and	dying	cells,	allowing	the	formation	of	either	LL-37-nDNA	and/or	LL-37-mtDNA	
complexes.	The	formation	of	either	the	nDNA	or	mtDNA	complexes	are	thought	to	play	a	similar	role	
(53).	mtDNA	contains	 similar	unmethylated	CpG	 repeats	 to	bacterial	DNA,	 leading	 to	augmented	
secretion	of	IFN-α	with	LL37-mtDNA	in	comparison	to	LL37-nDNA.	Thus,	the	LL37-mtDNA	complex	
might	 display	 stronger	 inflammatogenic	 properties	 than	 LL37-nDNA	 and	 might	 be	 highly	
inflammatory	in	vivo	(53,54).	LL37-mtDNA	complex	was	retained	in	the	loading	wells,	suggesting	that	
LL37-mtDNA	complex	is	resistant	to	DNase	II	digestion.	mtDNA	alone	could	be	easily	degraded,	which	
imply	 that	 LL37	protects	mtDNA	 from	degradation.	More,	 LL37-mtDNA	stimulation	 increased	 the	
number	of	TLR-9-positive	endosome,	triggering	activation	of	TLR-9	and	secretion	of	chemokines	and	
cytokines.	This	leads	to	an	exacerbate	inflammation	by	stimulating	IFN-α	production	in	pDCs	(53).	
mtDNA	 is	 susceptible	 to	 oxidation,	 a	 proinflammatory	modification	 detected	 in	 SLE	 sera.	
LL37	 complexed	 with	 oxidized	 mtDNA	 (Ox-mtDNA)	 enables	 their	 uptake,	 resulting	 in	 a	 10-fold	
enhance	of	“normal”	TLR-9-dependent	 IFN-α	 levels	 (54).	However,	another	study	mentioned	that	
both	mtDNA	and	Ox-mtDNA	in	complex	with	LL37,	were	able	to	promote	IFN-α	production	by	pDCs,	
but	mtDNA	complexed	with	LL37	resulted	in	significantly	more	IFN-α	release	than	the	oxidized	form	
(117).	 In	pDCs	it	was	also	shown	that	stimulation	with	mtDNA	resulted	in	a	significant	 increase	in	
expression	of	CD86,	CD83,	TFN-α	and	IL-8,	and	that	phenotypic	maturation	of	pDCs	is	 induced	by	
mtDNA	 as	well	 as	 oxidized	mtDNA,	mediated	 through	 TLR-9.	 Thus,	 human	 pDCs	may	 serve	 as	 a	
primary	sensor	for	mtDNA,	inducing	maturation,	migration,	and	type	I	IFN	production	of	pDCs	(117).	
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CAL-1	cell	line	
	
In	2005,	Maeda	et	al.	were	successful	in	establishing	of	a	novel	cell	line,	CAL-1,	which	shares	
many	similarities	with	pDCs.	Primary	malignant	cells	were	obtained	from	the	peripheral	blood	of	a	
patient,	a	76-year-old	male,	who	had	a	skin	tumor	on	his	back,	whose	lymph	node	biopsy	revealed	a	
blastic	NK	cell	lymphoma	diagnosis	according	to	the	WHO	classification,	that	was	later	found	to	have	
CD4+	CD56+	hematolymphoid	neoplastic	 features	 (118).	CD4+CD56+	hematodermic	neoplasm	and	
blastic	NK-cell	lymphoma	is	now	called	Blastic	pDC	neoplasm,	and	is	a	hematopoietic	malignancy	of	
pDC	origin	(30).	The	derived	cell	line,	CAL-1	cells,	were	found	to	express	mRNA	for	TLR-2,	-4,	-7	and	
-9.	Also,	this	cell	line	does	not	express	lineage-associated	markers	of	CD3,	CD14,	CD19,	CD16,	and	
CD11c	but	shows	positive	results	for	CD4,	CD56,	CD45RA,	HLA-DR,	CD123	and	CD38.	Morphologically	
CAL-1	are	large	blastoid	cells	with	agranular	prominent	basophilic	abundant	cytoplasm,	pale	Golgi	
area,	and	an	eccentric	nucleus	with	1	or	2	nucleoli.	Thus,	CAL-1	cells	resemble	plasma	cells,	have	
slight	nuclear	irregularity	with	a	large	nucleolus,	abundant	mitochondria,	and	parallel	arrays	of	rough	
endoplasmic	 reticulum	 (RER)	 but	 no	 Russell	 bodies.	 These	 results	 are	 similar	 when	 the	 authors	
compared	 primary	 cells	 and	 CAL-1	 cells	 in	 culture.	Moreover,	 both	 cells	 are	 weakly	 positive	 for	
CD11c,	CD7	and	granulocyte-macrophage	colony-stimulating	factor-α	(GM-CSFα),	positive	for	CCR5	
and	for	CXCR4	and	CXCR3.	CAL-1	cells	can	change	morphologically	into	the	mature	DC	phenotype	
after	short-term	culture	in	the	presence	of	GM-CSF	and	IL-3.	Three	days	after	exposure	to	GM-CSF	
or	IL-3,	cells	exhibit	many	long	dendrites,	leading	to	a	weak	up-regulation	of	expression	of	CD11c,	
CD13,	and	CD33	and	down-regulation	of	CXCR3	and	CXCR4.	CD80	and	CD86,	which	are	either	not	
expressed	or	present	on	unstimulated	CAL-1	cells,	are	up-regulated	upon	3	days	of	culture	 in	the	
presence	of	 IL-3.	After	stimulation	with	the	TLR-9	 ligands	CpG	ODNs,	the	cells	produce	significant	
levels	of	TNF-α	and	a	small	amount	of	IFN-α,	showing	some	aberrant	features,	maybe	due	to	their	
tumorigenic	origin	(118).	Thus,	CAL-1	cells	are	closely	related	to	the	pDC	lineage	while	having	some	
phenotypic	characteristics	different	from	those	of	pDCs,	namely:	a	more	blastoid	morphology	with	
large	 nucleoli;	 expression	 of	 CD33,	 CD7,	 and	 CD86,	 mRNA	 expression	 of	 TLR-2	 and	 TLR-4;	 and	
responsiveness	to	IL-3	and	GM-CSF	(118).		
Upon	activation,	CAL-1	cells	can	also	produce	large	amounts	of	type	I	IFNs	and	some	other	
proinflammatory	cytokines	through	TLRs/MyD88	signal	pathways.	More,	CAL-1	cells	present	several	
IRFs	 including	 IRF-1,	 IRF-3,	 IRF-5,	 IRF-8	and	NF-Kb	p50,	which	are	key	regulators	of	 IFN-β	and	IL-6	
expression	following	TLR-9-mediated	activation	(35).	Besides	the	activation	of	TLR-9	pathway,	the	
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stimulation	of	CAL-1	with	mimetics	for	exogenous	RNA	leads	to	activation	of	TLR-7,	also	resulting	in	
induction	of	proinflammatory	cytokines	(IL-6	and	TNF-α)	as	well	as	type	I	IFN	(119).	Human	CAL-1	
pDC-like	cell	line	can	thus	provide	novel	insights	into	regulation	of	TLR-7	and	9-mediated	activation	
of	human	pDCs.	CAL-1	 cells	mimic	 the	 response	of	human	pDCs	 to	CpG-B	 stimulation,	 triggering	
translocation	of	IRF-5	from	the	cytoplasm	to	the	nucleus,	increasing	expression	of	mRNA	encoding	
several	IRFs.	IRF-5	(but	not	IRF-1)	contributes	to	CpG-B	upregulation	of	IFN-β	and	IL-6	in	human	pDC,	
and	IRF-8	negatively	regulates	expression	of	these	genes.	These	regulation	factors	both	complex	with	
MyD88	in	resting	CAL-1	cells	(120).	
In	conclusion,	CAL-1	cells	share	many	phenotypical	similarities	with	pDCs	as	well	as	other	
functional	 characteristics	 such	 as	 nucleic	 acid	 recognition,	 TLR-9	 triggering	 upon	 stimulation	 and	
cytokine	expression,	which	is	interesting	in	establishing	CAL-1	cell	line	as	a	pDC	model.	Due	to	the	
paucity	of	circulating	primary	pDC,	having	a	cell	model	is	crucial	to	study	the	molecular	mechanisms	
that	may	trigger	and	ensue	progression	of	the	autoimmune	diseases.	However,	activation	of	CAL-1	
cells	with	these	complexes	are	not	yet	studied.	
	
	
Objectives	
	
The	main	goal	of	this	thesis	is	to	establish	a	cell	model	to	study	activation	of	human	pDCs	with	
immune	complexes.	Thus,	our	specific	objectives	are	to	optimize	stimulation	of	the	cell	line	CAL-1	
with	 LL37-self	 DNA	 complexes.	 For	 activation,	 we	 will	 optimize	 the	 concentration	 of	 both	 LL37	
peptide	and	DNA,	as	well	as	evaluate	activation	and	the	subsequently	early	endosome	and	TLR-9	
recruitment.	 We	 will	 also	 analyze	 possible	 differences	 between	 activation	 with	 nuclear	 DNA	 or	
mitochondrial	DNA.	
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Cell	culture	
	
	
CAL-1	cells	were	grown	in	RPMI	1640	medium	(Gibco,	USA)	supplemented	with	10%	of	heat-
inactivated	Fetal	Bovine	Serum,	1mM	Hepes	 (Gibco,	USA),	2mM	L-Glutamine	 (Gibco,	USA),	1mM	
Sodium	 Pyruvate	 (Gibco,	 USA)	 and	 Non-essencial	 Aminoacids	 1x	 (Gibco,	 USA)	 (73).	 Cells	 were	
cultured	 at	 37°C	 in	 CO2	 in	 an	 air	 incubator	 and	 plated	 every	 two	 days	 to	 a	 cell	 density	 of	
0.3x106cells/ml.	Different	 sera	batch	 from	different	 suppliers	were	 tested,	namely	 Sigma	 (F7524,	
Sigma-Aldrich,	 USA),	 PAN	 Biotech	 (P30-1401,	 PAN	 Biotech,	 Germany),	 BioWest	 (S1810,	 BioWest,	
USA),	HyClone	(SV30160,	HyClone,	USA),	Gibco	(10500064,	Gibco,	USA)	and	another	different	one	
from	Sigma,	gently	provided	by	Philippe	Pierre	(CIML,	Marseille).	Every	serum	was	thawed	at	4°C	
overnight	and	then	inactivated	by	heat	at	56°C	for	30minutes.	To	evaluate	CAL-1	growth,	the	number	
of	 cells	with	each	 serum	was	 counted	at	 0h,	 24h,	 48h,	 72h	and	96h,	 starting	with	 the	 same	 cell	
number	(9x104cells).	Cell	viability	was	also	measured	in	each	time	point	upon	staining	with	Propidium	
Iodide	(1mg/ml)	(Sigma-Aldrich,	USA),	measured	by	Flow	Cytometry	in	BD	Accuri	C6	Cytometer,	and	
compared	with	the	control	condition	(with	no	Propidium	Iodide).	The	control	condition	was	used	to	
perform	the	gating.	
	
	
Preparation	of	DNA-complexes	
	
To	test	activation	of	CAL-1	cells	with	immunocomplexes	formed	with	LL37,	CAL-1	nDNA	and	
mtDNA	were	firstly	 isolated.	For	nDNA	isolation,	cells	were	expanded	to	obtain	a	final	number	of	
107cells.	The	pellet	of	cells	was	collected	by	centrifugation	at	300g	for	6	minutes,	and	self-nDNA	from	
the	pellet	was	isolated	using	the	NZY	tissue	nDNA	isolation	kit	(NZYTech,	Portugal).	First,	cells	were	
resuspended	 in	200μl	Buffer	NT1.	 Then,	25μl	 Proteinase	K	 solution	and	200μl	of	Buffer	NL	were	
added	and	mixed	thoroughly	by	vortexing,	and	incubated	at	56°C	for	15minutes	(the	vortex	was	used	
occasionally	during	the	incubation).	Next,	210μl	of	100%	ethanol	was	added	to	the	sample	and	mixed	
immediately	 by	 vortex.	 The	mixture	was	 transfer	 into	 a	 NZYSpin	 Tissue	 Column	 placed	 in	 a	 2ml	
collection	 tube	 and	 centrifuge	 for	 1minute	 at	 11000g.	 The	 supernatant	 was	 discarded	 and	 the	
column	was	placed	in	a	new	collection	tube.	Then,	500μl	of	Buffer	NW1	was	added	to	the	column	
and	centrifuged	again	for	1minute	at	11000g.	The	supernatant	was	discarded	and	the	column	was	
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placed	back	into	the	collection	tube.		Next,	600μl	of	Buffer	NW2	(with	previous	addition	of	ethanol	-	
28ml	of	 100%	molecular	 biology	 grade	ethanol	 to	 each	bottle	 of	 buffer	NW2)	was	 added	 to	 the	
column	and	centrifuged	again	for	1minute	at	11000g,	then	discarding	the	flow-through	and	placing	
the	 column	 back	 into	 the	 collection	 tube.	 Another	 centrifugation	 of	 2minutes	 at	 11000g	 was	
performed	to	dry	the	membrane.	Finally,	the	column	was	placed	into	a	clean	microcentrifuge	tube	
and	100μl	of	sterile	water	was	added	directly	in	the	membrane	column,	incubated	for	1minute	at	
room	temperature	and	centrifuge	at	11000g	for	2minutes	to	elute	the	DNA.	DNA	quantity	and	quality	
were	then	evaluated	with	Nanodrop	(Denovix,	USA).	DNA	was	stored	at	-20°C.	
To	 isolate	 mtDNA,	 cells	 were	 expanded	 to	 obtain	 a	 final	 number	 of	 108cells	 and	 then	
submitted	to	differential	centrifugation.	A	pellet	of	108cells	was	first	collected	by	centrifugation	at	
300g	 for	 6minutes.	 The	 supernatant	was	 discarded	 and	 the	 pellet	was	washed	 2x	with	 PBS	 and	
centrifuged	at	300g	for	6minutes	to	obtain	a	clean	cell	pellet.	Then,	the	pellet	was	resuspended	in	
2ml	 of	 isolation	 buffer	 (10mM	 HEPES	 pH=7,5,	 250mM	 Sucrose,	 1mM	 EGTA,	 5g/L	 BSA)	 and	
centrifuged	at	500g	for	a	maximum	of	2minutes.	The	supernatant	was	discarded	and	the	pellet	was	
resuspended	in	3ml	of	isolation	buffer	and	homogenized	with	a	potter.	Then,	the	homogenate	was	
centrifuged	at	1500g	for	a	maximum	of	10minutes.	The	supernatant	was	kept	and	the	pellet	was	
homogenized	and	centrifuged	again	at	1500g	for	a	maximum	of	10minutes.	The	supernatant	was	
added	 to	 the	 supernatant	 obtained	 previously	 and	 centrifuged	 at	 10000g	 for	 a	 maximum	 of	
10minutes.	The	resultant	mitochondrial	pellet	was	washed	with	isolation	buffer	without	BSA	(121).	
After	isolation	of	the	mitochondrial	fraction,	mtDNA	was	isolated	using	the	NZY	tissue	nDNA	isolation	
kit	(NZYtech,	Portugal),	as	described	earlier,	and	kept	at	-20°C.	
Some	authors	refer	that	complexes	can	be	generated	by	mixing	1μg	of	self-nDNA	with	10μg	
LL37	(final	concentration	of	50μg/ml	or	10μM)	(34).	Here,	a	titration	was	performed	to	determine	
the	best	concentration	of	LL37	and	DNA	to	activate	CAL-1	cells.		
	 Immunocomplexes	 of	 nDNA	 with	 LL37	 peptide	 (InvivoGen,	 USA)	
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-C’)	were	thus	prepared	to	test	the	best	concentration	
of	 LL37.	 Here,	 1µg/ml	 of	 nDNA	 was	 used	 to	 prepare	 complexes	 with	 four	 different	 final	
concentrations	of	LL37	(50µg/ml,	20µg/ml,	10µg/ml	and	5µg/ml).	Immunocomplexes	were	prepared	
first	 in	20μl	of	PBS	for	30	minutes	at	room	temperature	and	then	diluted	 into	200μl	of	complete	
medium	(34).	
To	test	 the	best	quantity	of	nDNA	and	mtDNA	to	use	 in	the	 immunocomplexes,	different	
concentrations	 of	 both	 nDNA	 and	mtDNA	were	 used,	 namely	 1µg/ml,	 0.5µg/ml	 and	 0.2µg/ml	 of	
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nDNA/mtDNA,	both	with	10µg/ml	of	LL37,	except	in	the	first	that	stimulation	was	tested,	where	was	
only	tested	one	concentration	of	0.5µg/ml	of	mtDNA.	
	
	
Cell	stimulation	
	
CAL-1	cells	have	some	particularities	regarding	its	stimulation,	being	necessary	to	reduce	the	
serum	concentration	before	stimulation.	Here,	new	RPMI	1640	medium	was	prepared	but	this	time	
supplemented	 with	 1%	 of	 heat-inactivated	 FBS	 (119).	 To	 test	 activation,	 cells	 were	 washed	 by	
centrifugation	at	1200rpm	(~300g)	for	6minutes	and	counted	in	a	neubauer	chamber	with	Trypan	
Blue	(Sigma-Aldrich,	USA).	Then,	cells	were	resuspended	in	medium	with	1%	FBS	in	a	cell	density	of	
1x106cells/ml	 (122).	 Cells	 were	 incubated	 overnight	 (12-16h)	 at	 37°C	 in	 CO2	 in	 an	 air	 incubator,	
containing	1ml	of	cell	suspension	for	each	condition,	in	a	24-well	plate.	Cells	were	mycoplasma	free.	
To	select	a	serum	batch,	after	the	overnight	incubation,	cells	were	stimulated	with	3µM	CpG-
ODN	2216	 	 (Tebu-bio,	France)	 (122)	at	different	 time-points	 (3h,	6h	and	9h)	 (73)	comparing	 to	a	
control	condition	with	no	stimulation	(0h)	and	cultured	at	37°C	in	CO2	in	an	air	incubator.	After	each	
time-point,	 the	 cell	 pellet	 was	 collected	 by	 centrifugation	 at	 1200rpm	 (~300g)	 for	 6minutes,	 to	
further	mRNA	evaluation.	
To	test	the	activation	of	CAL-1	cells	with	 immunocomplexes	of	DNA	with	LL37,	cells	were	
seeded	 in	 a	well	 of	 24-well	 plate	 and	 cultured	 overnight	 (12-16h)	with	 1%	 FBS	medium	 (Sigma-
Aldrich,	USA),	before	setting	up	the	experiment.	As	before,	cells	were	seeded	at	106cells/ml.	Thus,	
0.75x106cells	were	cultured	in	550µl	of	1%	FBS	supplemented	RPMI	1640	medium	in	a	well	of	24-
well	plate	and	cultured	overnight	(12-16h)	at	37°C	in	a	CO2	in	air	incubator.	Then,	200µl	of	medium	
containing	the	immunocomplexes	were	added	to	the	cells	in	culture.	Two	different	time-points	were	
tested:	6h	to	evaluate	the	expression	of	cytokines	mRNA	(IFN-α,	IFN-β	and	TNF-α)	by	RT-qPCR	and	
24h	to	evaluate	 the	cytokines	secretion	by	ELISA.	Some	conditions	were	also	 tested	as	a	control,	
namely	cells	alone,	cells	only	with	the	addition	of	nDNA,	cells	only	with	the	addition	of	LL37,	all	in	
parallel	with	3µM	CpG-A	ODN	2216	(73)	activation	to	compare	the	activation	pattern.	When	it	comes	
to	mtDNA	experiment,	mtDNA	alone	was	also	added	as	a	control.		
After	each	time	point	for	 immunocomplexes,	the	content	of	every	well	was	collected	and	
placed	in	a	different	microcentrifuge	tube	and	an	aliquot	of	50µl	was	saved	to	perform	a	viability	
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test.	 Cell	 viability	 was	 measured	 for	 each	 time	 point	 by	 Propidium	 Iodide	 (Sigma-Aldrich,	 USA)	
staining,	 measured	 by	 Flow	 Cytometry	 in	 BD	 Accuri	 C6	 Cytometer.	 The	 remaining	 volume	 was	
centrifuged	 for	 6minutes	 at	 300g.	 The	 supernatant	 was	 stored	 and	 separated	 in	 four	 different	
aliquots	of	120µl	to	evaluate	the	cytokines	production	by	ELISA.	The	pellet	was	also	stored	to	isolate	
the	RNA	and	evaluate	the	cytokine	production	by	RT-qPCR.	
	 	
	
Measuring	RNA	levels	by	qPCR	
	
RNA	from	each	sample	was	isolated	using	the	RNeasy	Mini	Kit	(Qiagen,	Germany).	Here,	to	
the	cell	pellet	collected	by	previous	centrifugation,	350µl	of	Buffer	RLT	and	the	same	volume	of	70%	
ethanol	and	was	added,	mixing	well	by	pipetting.	Then,	up	to	700μl	of	the	sample	was	transferred,	
including	 any	 precipitate,	 to	 an	 RNeasy	 Mini	 spin	 column	 placed	 in	 a	 2ml	 collection	 tube,	 and	
centrifuged	 for	 15seconds	 at	 10000g.	 The	 flow-through	was	 discarded	 and	DNase	 digestion	was	
proceeded.	Here,	350μl	Buffer	RW1	was	added	to	RNeasy	column	and	centrifuged	for	15seconds	at	
10000g.	The	flow-through	was	discard.	Then,	DNA	digestion	was	proceeded	using	the	RNase-Free	
DNase	 Set	 (Qiagen,	 Germany).	 Here,	 a	 DNase	 I	 incubation	mix	 containing	 10μl	 of	 DNase	 I	 stock	
solution	and	70μl	Buffer	RDD	was	first	prepared	for	each	sample	and	mixed	gently	by	inversion	of	
the	tube	and	centrifuged	briefly.	After	the	centrifugation,	80μl	of	the	mix	was	directly	put	on	RNeasy	
column	membrane	 and	 left	 placed	 on	 benchtop	 (20–30°C)	 for	 15minutes.	 To	 conclude	 the	DNA	
digestion	steps,	350μl	of	Buffer	RW1	was	added	to	RNeasy	column,	centrifuged	for	15seconds	at	
10000g	and	the	flow-through	was	discarded.	
Then,	 500μl	 of	 Buffer	 RPE	 was	 added	 to	 the	 RNeasy	 spin	 column	 and	 centrifuged	 for	
15seconds	at	10000g,	discarding	the	flow-through.	After	that,	500μl	of	Buffer	RPE	was	added	to	the	
RNeasy	spin	column	and	centrifuge	for	2minutes	at	10000g.	The	column	was	placed	into	a	new	2ml	
collection	 tube	 and	 centrifuge	 at	 full	 speed	 for	 1minute	 to	 dry	 the	membrane.	 The	 column	was	
transferred	again,	this	time	into	a	new	1.5ml	collection	tube,	40μl	RNase-free	water	was	directly	put	
in	the	column	membrane	and	centrifuged	for	1minute	at	10000	g	to	elute	the	RNA.		
	 All	the	RNA	samples	were	obtained	with	RNeasy	Mini	Kit	(Qiagen,	Germany),	except	for	the	
samples	where	the	quantity	of	LL37	in	the	immunocomplexes	was	tested.	Here,	another	kit	was	used,	
namely	 NZY	 Total	 RNA	 Isolation	 kit	 (NZYtech,	 Portugal).	 Before	 starting	 the	 procedure,	 for	 each	
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sample,	 10µl	 of	 2-mercaptoethanol	 need	 to	 be	 added	 to	 1ml	 of	 Buffer	 RLT	 before	 use	 and	 four	
volumes	of	ethanol	(96-100%)	need	to	be	added	to	Buffer	RPE	for	a	working	solution.	After	collect	
the	pellet	samples,	350μl	of	buffer	NR	and	3.5μl	β-mercaptoethanol	were	added	to	the	pellet	and	
vortexed	vigorously.	Then,	the	lysate	was	put	into	an	NZYSpin	homogenization	column	placed	in	a	
2ml	 collection	 tube	 and	 centrifuged	 for	 1minute	 at	 11000g,	 saving	 the	 flow-through.	 The	 flow-
through	was	placed	into	a	new	1.5ml	microcentifuge	tube	and	350μl	of	70%	ethanol	was	added	and	
mixed	 immediately	by	pipetting	up	and	down	 (not	 centrifuging).	The	 lysate	was	 loaded	 in	n	new	
NZYSpin	Binding	column	and	centrifuged	at	11000g	for	30seconds.	The	flow-through	was	discarded	
and	 the	 column	 placed	 into	 a	 new	 collection	 tube.	 Then,	 350μl	 of	 Buffer	 NI	 was	 added	 and	
centrifuged	at	11000g	for	30seconds,	the	flow-through	was	discarded	and	the	column	was	placed	
back	into	the	collection	tube.	
	 To	purify	the	RNA	content,	DNA	digestion	was	proceeded.	For	each	sample,	a	Digestion	Mix	
was	prepared	using	10μl	of	DNase	I	and	90μl	of	digestion	buffer.	In	the	center	of	the	silica	membrane	
of	the	column,	95μl	of	the	Digestion	Mix	was	directly	added	and	incubated	at	room	temperature	for	
15minutes.	After	the	incubation,	200μl	of	Buffer	NWR1	was	added	and	centrifuged	for	1minute	at	
11000g.	The	supernatant	was	discard	and	the	column	was	placed	 in	a	new	collection	tube.	Then,	
600μl	 of	 Buffer	 NWR2	 was	 added	 and	 centrifuged	 at	 11000g	 for	 1minute,	 discarding	 the	 flow-
through	and	placed	 the	column	back	 in	 the	collection	 tube.	This	 step	was	 repeated,	washing	 the	
membrane	with	250μl	of	Buffer	NWR2	again	and	centrifuged	at	11000g	twice	for	1minute	to	dry	the	
column	membrane.	The	flow-through	was	discarded,	the	column	was	placed	in	a	clean	1,5ml	RNase-
free	 microcentrifuge	 tube	 and	 50μl	 of	 RNase-free	 water	 was	 added	 directly	 to	 the	 column	
membrane.	Finally,	the	sample	was	centrifuged	at	11000g	for	1minute	to	elute	the	RNA.		
After	isolation,	the	quantity	and	the	quality	of	the	RNA	was	measured	with	the	nanodrop,	
using	nuclease-free	H2O	as	control.	The	resultant	A260/280	ratios	were	between	1.9	and	2.1.	The	
resultant	RNA	was	saved	at	-80°C.		
To	evaluate	cytokines	mRNA	expression,	cDNA	synthesis	for	each	condition	needed	to	be	
prepared	in	order	to	perform	the	RT-qPCR.	
To	perform	the	reverse	transcription	(cDNA	synthesis),	one	microcentrifuge	tube	for	each	
condition	was	prepared,	containing	500ng	of	RNA	of	each	sample,	1µl	of	dNTP	Mix	10mM	(NZYtech,	
Portugal),	 2µl	 of	 random	hexamers	 (100ng/µl)	 (Invitrogen,	USA)	 and	 nuclease	 free	water	 (Fisher	
Scientific,	USA),	for	a	final	volume	of	20µl.	The	content	of	the	tubes	was	mixed	well	and	then	the	
mixture	was	heated	to	65°C	for	5minutes,	followed	by	a	quick	chill	on	ice	of			approximately	2minutes.	
	
	
	
|	MATERIALS	&	METHODS	|	
	
25	
The	samples	were	centrifuged	briefly	and	7µl	of	the	above	mix	was	added	to	each	sample	and	mixed	
gently,	followed	by	an	incubation	of	2minutes	at	25°C.	Finally,	1µl	of	SuperScript	II	RT	(Invitrogen,	
USA)	was	added,	mixed	gently	and	the	final	mix	was	put	in	a	thermocycler	to	perform	the	reverse	
transcriptase	 cycle	 (incubate	 for	 10minutes	 at	 25°C,	 followed	 by	 50minutes	 at	 42°C;	 reaction	
inactivation	by	heating	at	70°C	for	15minutes,	followed	by	4°C	incubation).	The	resultant	cDNA	in	
the	tubes	were	kept	at	-20°C.	
RT-qPCR	was	performed	with	the	primers	(all	from	Invitrogen,	USA)	on	Table	1.		
Table	1	–	Primer	sequences	for	each	target	gene.	
Gene	 Sequence	
GAPDH	–	Forward	 5’-CAATGACCCCTTCATTGACC-3’	
GAPDH	-	Reverse	 5’-TCTGGTCATGAGTCCTTCCA-3’	
IFN-α	–	Forward	 5’-TGATCCAGCAGATCTTCAAT-3’	
IFN-α	–	Reverse	 5’-CAGCTGCTGGTAGAGTTCA-3’	
IFN-β	–	Forward	 5’-TGCTTGGATTCCTACAAAGA-3’	
IFN-β	–	Reverse	 5’GGATGTCAAAGTTCATCCTG-3’	
TNF-α	–	Forward	 5’-CCCTCAGCAAGGACAGCAGA-3’	
TNF-α	–	Reverse	 5’-AGCCGAGGGTCAGTATGTGAG-3’	
	
For	qPCR,	to	each	well	it	was	added	a	mix	containing	2µl	of	cDNA	(diluted	1:10),	10µl	of	SYBR	
Premix	(Clontech,	USA),	0.4µl	of	PCR	forward	primer,	0.4	µl	of	PCR	reverse	primer,	0.08	µl	of	ROX	
Dye	(Clontech,	USA)	and	7.12µl	of	nuclease-free	H2O,	in	a	final	volume	of	20µl	per	well.		
The	 plate	 was	 centrifuged	 for	 2minutes	 at	 1000g.	 The	 qPCR	 was	 proceeded	 using	 the	
standard	run	(initial	denaturation:	1x	95℃	30seconds;	PCR:	40x	95℃	5seconds	+	60℃	30-34seconds;	
and	dissociation	stage:	30seconds)	in	a	7500	Real	Time	PCR	System,	from	Applied	Biosystems.	
All	samples	were	analyzed	using	these	reagents,	except	for	the	third	experiment	regarding	
optimization	of	LL37	concentrations.	 In	this	experiment,	for	reverse	transcription,	cDNA	Synthesis	
SuperMix	(Bimake,	USA)	was	used.	For	that,	500ng	of	each	sample	of	RNA	(up	to	8	μl),	2μl	of	5×qRT	
SuperMix	(Bimake,	USA)	and	RNase-free	Water	up	to	10μl	were	used	to	produce	cDNA.	After	sample	
preparation,	 they	were	 incubated	 in	 the	 thermocycler	 at	 25°C	 for	 10	minutes,	 then	 at	 42°C	 for	
30minutes	for	extension,	and	finally	at	85°C	for	5minutes	to	terminate	the	reaction.	The	tubes	were	
stored	at	-20°C	or	proceeded	directly	with	the	RT-qPCR.	
For	RT-qPCR,	the	analysis	was	proceeded	in	triplicates.	To	each	well,	a	total	of	20μl	of	a	mix	
composed	 for	 2μl	 cDNA,	 10μl	 SYBR	 LowRox	 (Bimake,	USA),	 0.6μl	 PCR	 forward	 primer,	 0.6μl	 PCR	
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reverse	 primer	 and	 6.8μl	 H2O,	 were	 added.	 	 Once	 the	 plate	 preparation	was	 completed,	 it	 was	
centrifuged	for	3minutes	at	1000g.	Finally,	the	qPCR	was	proceeded	using	the	standard	run	(holding	
stage:	 95℃	 5minutes;	 cycling	 stage	 40x:	 95℃	 15seconds	 +	 60℃	 60seconds;	 melt	 curve:	 95°C	
15seconds	+	 60°C	60seconds	+	 95°C	15seconds),	 in	 a	 7500	Real	 Time	PCR	 System,	 from	Applied	
Biosystems.	
	
	
Measuring	cytokine	secretion	by	ELISA	
	
To	evaluate	secretion	of	TNF-α	or	IL-1β,	ELISA	assays	were	performed	using	Human	TNF-	α	
or	 Human	 IL-1β	Mini	 TMB	 ELISA	 Development	 Kits,	 respectively	 (Peprotech,	 UK).	 First,	 100µl	 of	
monoclonal	mouse	anti-hTNF-α	or	anti-hIL-1β	capture	antibody	(1x	in	PBS)	was	added	immediately	
to	each	ELISA	plate	well	and	 incubated	overnight	at	 room	temperature.	Wells	were	washed	 four	
times	using	300µl	of	wash	buffer	(0.05%	Tween-20	in	PBS)	per	well.	In	the	last	wash,	the	plate	was	
inverted	to	remove	the	residual	buffer	and	blot	on	paper	towel.	Then,	300µl	of	block	buffer	(1%	BSA	
in	PBS)	was	added	to	each	well	and	 incubated	 for	at	 least	1hour	at	 room	temperature.	After	 the	
incubation,	the	wells	were	aspirated	to	remove	liquid	and	washed	four	times	using	300µl	of	wash	
buffer	(0.05%	Tween-20	in	PBS)	per	well.	
To	make	a	standard	curve	for	the	evaluation	of	TNF-α,	the	Human	TNF-α	Standard	solution	
was	diluted,	in	the	plate,	from	2000pg/ml	to	zero	in	diluent	(0.05%	Tween-20,	0.1%	BSA	in	PBS).	To	
make	a	standard	curve	for	the	evaluation	of	IL-1β,	the	Human	IL-1β	Standard	solution	was	diluted,	
in	the	plate,	from	750pg/ml	to	zero	in	diluent.	Also,	100µl	of	samples	were	added	to	each	respective	
well.	The	plate	was	incubated	at	room	temperature	for	at	least	2	hours.	The	wells	were	washed	four	
times	using	300µl	of	wash	buffer	(0.05%	Tween-20	in	PBS)	per	well.	Then,	100µl	of	biotinylated	rabbit	
anti-hTNF-α	 or	 goat	 anti-human	 IL-1β	 (0.15µg/ml	 or	 0.25µg/ml,	 respectively)	 were	 added	 and	
incubated	at	room	temperature	for	2hours.	The	wells	were	washed	again	four	times	and	100µl	of	
Streptavidin-HRP	 (0.05µg/ml	 for	 TNF-α	 and	 0.075	 µg/ml	 for	 IL-1β)	 was	 added.	 The	 plate	 was	
Incubated	for	30minutes	at	room	temperature	and	100µl	of	TMB	Liquid	Substrate	was	added	to	each	
well	after	incubation	and	after	the	four	washes.	The	substrate	was	incubated	at	room	temperature	
for	color	development	for	20minutes.	Finally,	100µl	of	Stop	Solution	(1M	HCl)	was	added	to	each	
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well	and	the	color	development	was	detected	with	a	spectrophotometer	(TECAN	Infinite	M200)	using	
450nm	as	primary	wave	with	wavelength	correction	set	at	620nm.	
To	evaluate	the	secretion	of	IFN-α,	an	ELISA	assay	was	performed	using	IFN	alpha	Human	
Matched	Antibody	Pair	(ThermoFisher	Scientific,	USA).	First,	100µl	monoclonal	coating	antibody	to	
Human	IFN-α	(1µg/ml)	of	the	diluted	coating	antibody	was	added	to	each	well	of	the	ELISA	plate	and	
incubated	overnight	at	4°C.	Wells	were	washed	once	using	400µl	of	wash	buffer	(0.05%	Tween-20	in	
PBS	1x)	per	well,	and	250µl	of	assay	buffer	(5g	BSA	and	0.5ml	Tween-20	in	1L	PBS	1x)	was	added	to	
each	well	and	 incubated	for	at	 least	2hours	at	room	temperature.	After	the	 incubation,	the	wells	
were	washed	twice	using	400µl	of	wash	buffer	(0.05%	Tween-20	in	PBS).	
To	make	a	standard	curve	for	the	evaluation	of	IFN-α,	the	Human	IFN-α	Standard	protein	
(1ng/ml)	was	diluted,	in	the	plate,	from	500	to	7.8pg/ml	in	Assay	Buffer.	Then,	80µl	of	Assay	Buffer	
and	20µl	of	each	sample	were	added	to	the	sample	wells.	Also,	50µl	of	HRP-Conjugate	anti-human	
IFN-α	monoclonal	antibody	diluted	in	Assay	Buffer	(1:1000)	were	added	to	all	wells.	The	plate	was	
incubated	 at	 room	 temperature	 for	 2hours,	 on	 a	 microplate	 shaker	 set	 at	 400rpm.	 Then,	 the	
microwells	 were	 washed	 three	 times	 and	 100µl	 of	 Substrate	 Solution	 (1:2	 H2O2	 in	
Tetramethylbenzidine)	was	added	and	incubated	at	room	temperature	for	about	10minutes,	to	allow	
color	development.		
The	 substrate	 reaction	 was	 stopped	 by	 quickly	 pipetting	 100µl	 of	 Stop	 Solution	 (1M	
Phosphoric	Acid)	 into	each	well.	Finally,	the	resultant	absorbance	of	each	microwell	was	red	on	a	
spectrophotometer	(TECAN	Infinite	M200)	using	450nm	as	primary	wave	with	wavelength	correction	
set	at	620nm.	
	
	
Analysis	of	complex	recognition	by	Immunofluorescence	
	
The	 evaluation	 of	 the	 immunocomplex	 entrance	 within	 endosomes	 (rabbit	 monoclonal	
antibody	 anti-EEA1	 clone	 F.43.1,	 ThermoFisher	 Scientific,	 USA)	 and	 TLR-9	 recruitment	 (mouse	
monoclonal	 antibody	 anti-TLR-9	 clone	 26C593,	 Santacruz	 Biotech,	 USA)	 was	 performed	 by	
immunofluorescence.	Here,	 to	 identify	 the	 complexes,	 the	antibody	mouse	monoclonal	 antibody	
anti-LL37	conjugated	Alexa	Fluor	488	clone	D-5	(Santacruz	Biotech,	USA)	was	used.	To	perform	the	
immunofluorescence	 experiment,	 coverslips	 were	 first	 treated	 with	 Alcian	 Blue	 solution	 (Sigma-
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Aldrich,	USA)	and	heated	at	microwave	until	boiling,	followed	by	washing	steps	first	with	distillated	
water,	 then	 with	 ethanol	 70%	 and	 again	 distillated	 water.	 Then,	 the	 coverslips	 were	 left	 drying	
individually	in	a	paper	towel.	
After	 stimulation	 with	 the	 immune	 complexes,	 cells	 were	 collected	 and	 centrifuged	 for	
6minutes	at	300g.	Then,	the	cell	pellet	was	resuspended	in	1ml	of	RPMI	1640	(without	supplements	
and	FBS)	and	50µl	were	placed	on	a	coverslip	pre-treated	with	Alcian	Blue.	Cells	were	incubated	for	
20minutes	in	an	air	incubator	at	37°C	5%	CO2.	The	cells	were	fixed	with	500µl	of	Paraformaldehyde	
(PFA)	4%	for	10minutes	at	room	temperature,	being	washed	before	with	PBS	1x	and	kept	in	PBS	until	
staining.	To	permeabilize	the	cells,	the	coverslip	was	covered	with	500µl	of	Permeabilization	Buffer	
(1%	glycine	 (1M),	 5%	FBS	and	0.1%	Triton-X)	 and	 incubated	 for	 5minutes.	After	 that,	 buffer	was	
removed	and	the	cells	were	covered	with	500µl	of	Staining	Buffer	(1%	glycine	(1M)	+	5%	FBS)	and	
incubated	for	10minutes.	
Different	concentrations	for	the	antibodies	were	tested	(Table	2).	
	
Table	2	-	Concentration	range	for	antibody	concentration	test.	
Antibody	 Concentration	
Mouse	anti-TRL9	 1:50	 1:100	 1:200	 1:500	
Mouse	anti-LL37-AF488	 1:100	 1:250	 1:500	 1:1000	
	
To	 incubate	 the	 primary	 antibodies,	 a	mix	was	 prepared	 by	 diluting	 the	 antibodies	with	
staining	buffer,	in	a	final	volume	of	50µl/sample,	which	was	added	to	each	coverslip.	The	coverslips	
were	 left	 incubating	for	45minutes	at	room	temperature	 in	a	wet	chamber.	After	 incubation,	 the	
coverslips	were	washed	three	times	for	5minutes	with	staining	buffer.		In	the	last	wash,	the	staining	
buffer	was	not	removed.	
The	monoclonal	antibody	mouse	anti-TLR-9	was	detected	with	the	secondary	antibody	Goat	
anti-mouse	IgG	Alexa	Fluor	568	(ThermoFisher	Scientific,	USA)	and	the	monoclonal	antibody	rabbit	
anti-EEA1	was	detected	with	Goat	anti-mouse	IgG	Alexa	Fluor	647	(ThermoFisher	Scientific,	USA).		
To	 incubate	 the	secondary	antibody,	a	mix	was	prepared	by	diluting	 the	antibodies	with	 staining	
buffer,	 in	a	 final	 concentration	of	1:500	 in	50µl/sample,	which	was	added	 to	each	coverslip.	The	
coverslips	were	 incubated	 for	 1hour	 at	 room	 temperature.	After	 incubation,	 the	 coverslips	were	
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washed	three	times	for	5minutes	with	staining	buffer.		In	the	last	wash,	the	staining	buffer	was	not	
removed.	
The	mouse	antibody	anti-LL37	conjugated	with	Alexa	Fluor	488	was	the	 last	to	be	added.	
Again,	 a	 mix	 was	 prepared	 by	 diluting	 the	 antibody	 with	 staining	 buffer,	 in	 a	 final	 volume	 of	
50µl/sample,	and	was	added	to	each	coverslip.	The	coverslips	were	left	incubate	for	1hour	at	room	
temperature.	Coverslips	were	washed	once	with	staining	buffer	and	twice	with	PBS.		In	the	last	wash,	
PBS	was	not	removed	and	the	coverslips	was	briefly	rinsed	in	distilled	water	and	gently	dried	in	a	
paper	towel	before	placing	on	slides	with	6μl	of	ProLong	(ThermoFisher	Scientific,	USA).	
After	defining	the	best	concentration	for	each	antibody,	staining	was	performed	following	
the	indicated	concentrations	on	Table	3.	To	better	understand	the	stimulation	pattern,	different	time	
points	(0h,	15min,	30min,	60min	and	120min)	of	cell	incubation	with	immunocomplexes	were	tested	
to	follow	progress	of	stimulation.		
	
	
Table	 3-	 Antibody	 concentration	 for	 evaluation	 of	 TLR-9	 and	 EEA1	 recruitment	 of	 immunocomplexes	 with	 endosomal	
internalization.	
Antibody	 Concentration	 Conjugate	 Concentration	
Mouse	anti-TRL9	 1:200	 Goat	anti-mouse	Alexa	Fluor	568	 1:500	
Rabbit	anti-EEA1	 1:200	 Goat	anti-rabbit	Alexa	Fluor	647	 1:500	
Mouse	anti-LL37-AF488	 1:200	 -	 -	
	
	
	
Statistical	Analysis	
	
All	 data	 regarding	 RT-qPCR	 and	 ELISA	 assays	 were	 statistically	 evaluated	 through	 the	
GraphPad	Prim®	software	v.7.00	(La	Jolla,	CA,	USA).	Each	experiment	was	repeated	five	times.	For	
each	 condition,	 a	 normality	 test	was	 performed	 to	 evaluate	 if	 the	 results	 came	 from	a	Gaussian	
distribution,	using	the	D’Agostino	and	Pearson	test.	Because	of	the	small	“n”	for	each	condition,	it	
was	not	possible	to	ensure	a	Gaussian	distribution.	However,	statistical	analysis	was	performed	by	
One-way	ANOVA	test,	assuming	normality.	No	statistically	differences	were	found	in	all	assays.	
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III. Results	&	Discussion	
	  
	
	
	
|	RESULTS	&	DISCUSSION	|	
32	
Serum	batch	choice	
	
	
The	behavior	of	pDCs	is	dependent	on	the	batch	of	serum	used	for	cell	culture,	being	crucial	
to	select	a	serum	that	allows	good	cell	viability	and	promotes	good	conditions	to	evaluate	activation	
of	the	cells.	In	order	to	find	one	batch	that	promoted	the	best	growth	conditions,	CAL-1	cells	were	
cultured	with	RPMI	1640	medium	supplemented	with	serum	from	different	suppliers.	A	serum	batch	
from	Sigma	that	has	been	previously	used	by	our	collaborators	(from	Marseille)	was	used	as	positive	
control	and	the	number	of	cells	was	counted	at	different	time	points	(0h,	24h,	48h,	72h	and	96h),	to	
evaluate	the	growth	of	cells	in	each	condition	(Table	4	and	Figure	2).	
	
Table	4-	Number	of	cells	after	culture	in	medium	with	10%	sera	from	different	suppliers,	at	different	time-points	(0h,	24h,	
48h,	72h	and	96h).	Data	was	obtained	by	diluting	a	cell	suspension	with	Trypan	Blue	and	counting	on	a	neubauer	chamber.	
	 	 0h	 24h	 48h	 72h	 96h	
Se
ru
m
	
Sigma	 9.00x104	 3.48x105	 1.57x106	 2.40x106	 4.40x106	
PAN	Biotech	 9.00x104	 3.10x105	 1.74x106	 2.00x106	 2.64x106	
BioWest	 9.00x104	 6.30x105	 1.89x106	 2.08x106	 4.16x106	
HyClone	 9.00x104	 4.30x105	 1.35x106	 2.52x106	 4.50x106	
Gibco	 9.00x104	 4.50x105	 1.46x106	 3.04x106	 4.60x106	
Sigma	(from	Marseille)	 9.00x104	 4.35x105	 1.01x106	 2.60x106	 5.00x106	
	
	
Figure	2-	Growth	curve	for	cells	grown	in	medium	supplemented	with	different	sera.	Live	cells	were	counted	after	diluting	
in	trypan	blue	for	each	time	point	indicated.	
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Overall,	cell	growth	did	not	suffer	major	changes	with	the	different	sera,	even	though	there	
were	 some	 small	 differences.	 After	 24h	 and	 48h	 of	 culture,	 the	 BioWest	 FBS	 was	 the	 one	 that	
promoted	highest	cell	growth	but	the	same	pattern	was	not	seen	after	72h	and	96h	in	culture.	After	
72h	 of	 culture,	 the	 serum	 from	 Gibco	 promoted	 a	 slightly	 higher	 growth.	 Also,	 after	 96h	 of	
stimulation,	there	was	a	decrease	on	the	cell	number	upon	culture	with	the	serum	from	PAN	Biotech.		
We	next	evaluated	cell	viability	at	the	same	time	points	by	Flow	Cytometry,	upon	Propidium	
Iodide	staining.	Graphs	with	the	gating	strategy	can	be	seen	as	an	example	on	Figure	3.	The	resultant	
percentage	of	viable	cells	can	be	seen	on	Table	5.	
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Figure	3	–	Flow	Cytometry	analysis	of	cell	viability	for	CAL-1	cells.	A	–selection	of	the	area	containing	events	considered	for	
analysis	of	cell	viability	(gating	–	P1	region);	B	–	viable	cells	will	not	stain	for	propidium	iodide	and	thus	are	located	in	the	
gated	area	(R1).	
	
	
Table	5	-	Percentage	of	viable	cells	for	each	serum	and	in	each	time	point.	The	percentage	was	obtained	by	Flow	Cytometry	
analysis	upon	Propidium	Iodide	staining.	
	 0h	 24h	 48h	 72h	 96h	
Sigma	 100%	 99.9%	 99.8%	 98.1%	 98.9%	
PANBiotech	 100%	 100%	 99.8%	 98.3%	 99.5%	
BioWest	 100%	 100%	 99.8%	 97.9%	 97.9%	
HyClone	 100%	 99.9%	 99.8%	 98.2%	 99.2%	
Gibco	 100%	 99.9%	 99.8%	 99.7%	 99.6%	
Sigma	(from	Marseille)	 100%	 99.9%	 99.9%	 99.7%	 99.8%	
	
All	sera	promoted	good	cell	viability,	with	the	percentage	of	viable	cells	being	above	97%	for	
all	time	points	analyzed.	Since	the	prospective	work	consists	 in	the	stimulation	of	CAL-1	cells,	the	
expression	level	of	cytokines	is	another	condition	to	consider	in	order	to	choose	a	serum	batch.	
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After	CAL-1	stimulation	with	3µM	CpG-A,	expression	of	IFN-α,	IFN-β	and	TNF-α	mRNA	was	
measured	by	RT-qPCR	at	different	time-points	(3h,	6h	and	9h)	comparing	to	the	control	(0h)	(Figure	
4).	These	cytokines	were	used,	since	their	expression	is	known	to	be	promoted	by	CpG-A	stimulation	
(73).	
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Figure	4	–	Expression	of	mRNA	for	IFN-α	(A),	IFN-β	(B)	and	TNF-α	(C)	was	determined	by	RT-qPCR	for	CAL-1	cells	cultured	in	
medium	supplemented	with	different	batches	of	serum	and	stimulated	with	CpG-A.	GAPDH	was	used	as	a	reference	gene	
and	mRNA	expression	was	normalized	against	values	obtained	for	0	h	of	incubation.	
	
	
In	general,	all	sera	batch	promoted	an	increased	expression	of	cytokine	mRNA	between	3-6h	
upon	stimulation.	The	HyClone	serum	led	to	a	low	expression	of	cytokines	and	thus	it	was	no	longer	
considered.	The	Gibco	serum	was	also	excluded	due	to	the	abrupt	decrease	in	cytokines	level	after	
6h	and	abrupt	increase	after	9h	of	stimulation,	showing	an	irregular	pattern	over	time.	Looking	at	
the	tendency	on	Figure	4-A,	the	serum	with	improved	expression	of	IFN-α	after	3h	of	stimulation	of	
CpG-A	 was	 the	 Sigma	 serum.	 After	 6h	 of	 stimulation,	 the	 BioWest	 serum	 showed	 the	 highest	
production	of	IFN-α,	followed	by	Sigma.	After	9h,	it	was	again	the	batch	from	Sigma	that	promoted	
more	IFN-α	production.	Observing	Figure	4-B,	after	3h	of	stimulation	both	PANBiotech	and	Sigma	
sera	showed	the	highest	expression	of	IFN-β.	However,	after	9h	the	Sigma	serum	led	to	a	diminished	
expression	of	IFN-β.	Finally,	looking	at	Figure	4-C,	even	though	expression	of	TNF-α	mRNA	remained	
very	low,	the	batch	from	Sigma	promoted	higher	expression	of	TNF-α	3h	after	stimulation,	followed	
by	a	decrease	at	6h	and	9h	post-stimulation.		
Thus,	every	serum	batch	promoted	a	good	growth	tendency	but	the	sera	that	seems	to	be	
more	efficient	to	study	the	activation	pattern	of	CAL-1	cell	 is	the	one	from	Sigma.	All	subsequent	
assays	were	performed	with	this	batch.	
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Optimizing	LL37	Concentration	for	CAL-1	stimulation	with	immune	complexes	
	
Our	goal	is	to	analyze	stimulation	of	CAL-1	cells	with	immune	complexes	formed	with	self-
DNA	conjugated	with	the	LL37	peptide.	However,	there	was	no	optimized	concentration	of	LL37	to	
form	these	complexes.	Therefore,	we	started	by	testing	different	concentrations	of	LL37,	based	on	
earlier	pDC	studies.	Lande	et	al.	2007	evaluated	IFN-α	production	upon	stimulation	with	IC	formed	
by	DNA	and	LL37	in	four	different	concentrations	(0.3µM,	1µM,	3µM	and	10µM)	in	primary	cells.	In	
their	assays,	the	 lower	concentration	of	the	peptide	had	no	effect	on	IFN-α	production.	Thus,	we	
selected	four	conditions	to	test,	namely	ICs	formed	with	5,	10,	20	and	50µg/ml,	corresponding	to	
the	concentrations	of	1,	2,	4	and	10µM,	respectively.	Firstly,	CAL-1	cell	viability	was	measured	by	
Flow	 Cytometry	 upon	 stimulation	 with	 immune	 complexes	 prepared	 with	 these	 different	
concentrations	for	6h	and	24h	(Figures	5	and	6).	The	gating	strategy	adopted	was	similarly	to	the	
one	previously	described	(Figure	2-A).	
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Figure	5	–	Evaluation	by	Flow	Cytometry	of	CAL-1	cells	viability	after	6h	of	stimulation	with	IC	with	different	concentrations	
of	LL37.	Plots	show	the	intensity	of	Propidium	iodide	staining	(FL2)	against	FCS.	The	percentage	of	events	(R6)	represents	
the	viable	cells.	A	–	cells	with	no	treatment;	B	–	cells	treated	with	IC	prepared	with	5µg/ml	of	LL37;	C	–	cells	treated	with	IC	
	
	
	
|	RESULTS	&	DISCUSSION	|	
37	
prepared	with	10µg/ml	of	LL37;	D	–	cells	treated	with	IC	prepared	with	20µg/ml	of	LL37;	E	–	cells	treated	with	IC	prepared	
with	50µg/ml	of	LL37.	
	
	
	
A.	
	
	 B.	
	
Figure	6	–	Percentage	of	viable	cells	after	6h	(A)	and	24h	(B)	of	incubation	with	immune	complexes	prepared	with	different	
LL37	concentrations	(5,	10,	20	and	50µg/ml).	Data	was	obtained	by	Flow	Cytometry	upon	Propidium	Iodide	staining.	
	
	
	 After	 6h	 of	 incubation,	 the	 control	 condition	 (CAL-1	 cells	 alone	 –	 Figure	 5-A)	 shows	 a	
percentage	of	 viable	 cells	 close	 to	90%,	 indicating	 some	cellular	death,	 as	expected.	This	 cellular	
death	increased	when	CAL-1	cells	were	stimulated	with	the	IC	containing	20µg/ml	of	LL37	and	even	
more	so	for	50µg/ml.	However,	lower	concentrations	of	LL37	in	the	complexes	allowed	for	a	higher	
percentage	of	viable	cells,	with	similar	 levels	to	the	control	conditions.	This	 	 is	 in	agreement	with	
previous	results	where	higher	concentrations	of	LL37	peptide	decreased		the	percentage	of	viable	
cells	 in	neutrophils	 (108).	However,	 in	 their	 studies,	Zhang	et	al.,	2008	 found	 that	 this	 cell	death	
induction	is	clearly	evident	only	when	doses	exceed	5µM.	This	may	not	be	true	for	pDCs/CAL-1	cells,	
since	cellular	death	seems	to	be	enhanced	in	doses	higher	than	4µM	(20µg/ml).	
We	next	evaluated	which	concentration	of	LL37	peptide	is	best	to	form	ICs	that	activate	CAL-
1.	For	that,	we	quantified	expression	of	mRNA	for	the	cytokines	IFN-α,	IFN-β	and	TNF-α	by	RT-qPCR	
upon	6h	of	CAL-1	stimulation	with	immune	complexes	formed	with	different	concentrations	of	LL37	
(Table	 6	 and	 Figure	 8).	 Cytokine	 expression	 was	 also	 evaluated	 for	 the	 conditions	 with	 24h	 of	
incubation.	 Nevertheless,	 no	 expression	 was	 detected,	 since	 cytokine	 mRNA	 is	 generally	 not	
detected	after	24h,	as	can	be	seen	on	earlier	results,	which	showed	a	reduction	after	9h	stimulation.	
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Table	6	-	Relative	amount	of	IFN-α,	IFN-β	and	TNF-α	mRNA	expressed	by	CAL-1	stimulated	with	the	complexes	formed	with	
the	indicated	amount	of	LL37,	measured	by	RT-qPCR,	after	6h	of	incubation.	
	 	
CAL-1	
alone	
DNA	
alone	
	
50µg/ml	
of	LL37	
20µg/ml	
of	LL37	
10µg/ml	
of	LL37	
5µg/ml	of	
LL37	
CpG	
IFN-α	
1st	test	 -	 1	 	 2.203	 0.798	 2.605	 3.577	 1.207	
2nd	test	 1	 2.269	 	 20.225	 0.069	 4.834	 2.569	 2.527	
3rd	test	 1	 0.303	 	 0.208	 0.298	 0.265	 0.476	 1.2	
4th	test	 1	 0.137	 	 0.149	 0.074	 544.284	 0.512	 283.432	
5th	test	 1	 0.310	 	 6.185	 0.459	 0.51	 0.437	 1.939	
IFN-β	
1st	test	 -	 1	 	 2.203	 0.849	 2.335	 3.053	 0.826	
2nd	test	 1	 1.666	 	 11.316	 0.055	 3.844	 1.629	 1.648	
3rd	test	 1	 0.287	 	 0.180	 0.371	 0.389	 0.391	 1.430	
4th	test	 1	 0.809	 	 0.048	 1.179	 8932.565	 1.299	 52.101	
5th	test	 1	 1.278	 	 1.442	 0.352	 0.362	 0.531	 2.351	
TNF-α	
1st	test	 -	 1	 	 0.869	 1.372	 1.015	 1.414	 1.731	
2nd	test	 1	 0.953	 	 0.808	 1.04	 0.665	 0.642	 0.711	
3rd	test	 1	 0.296	 	 0.23	 0.32	 0.245	 0.161	 1.116	
4th	test	 1	 0.619	 	 0.437	 0.937	 131.077	 0.069	 342.528	
5th	test	 1	 0.386	 	 0.394	 0.1	 0.301	 0.357	 1.009	
	
	
	
At	 the	 fourth	 test,	 values	were	extremely	high	 for	all	 cytokines	 (in	 red)	 for	 the	condition	
containing	10µg/ml	of	 LL37	 (Table	6),	 suggesting	 that	 some	contamination	might	have	occurred,	
which	 resulted	 in	 an	 outlier.	 Excluding	 these	 values	 from	 further	 analysis,	 some	 variability	 still	
remains	visible.	Indeed,	error	bars	were	very	high,	which	was	not	expected	since	we	were	working	
with	a	cell	line.	The	variability	between	assays	may	have	been	caused	by	the	reduced	shelf-life	of	the	
LL37	peptide	(one	month)	or	even	the	passage	of	cells	on	each	experiment,	which	varied	from	7	to	
23.	Thus,	these	assays	should	be	repeated	to	have	more	coherent	data.	At	these	stage,	no	statistically	
significant	differences	have	been	detected.	Nevertheless,	some	tendencies	were	evident.	In	general,	
the	immune	complexes	with	50µg/ml	of	LL37	peptide	promoted	higher	expression	of	IFN-α,	IFN-β	
and	a	lower	expression	of	TNF-α	(Figure	7).	However,	as	shown	earlier,	this	concentration	decreased	
cell	viability	(Figure	5).	Immune	complexes	with	10µg/ml	of	LL37	also	promoted	higher	expression	of	
IFN-α,	IFN-β	and	a	lower	expression	of	TNF-α,	even	though	at	lower	levels.	The	immune	complexes	
with	20µg/ml	of	LL37	decrease	the	expression	of	 IFN-α,	 IFN-β,	being	even	 lower	 than	CAL-1	cells	
alone,	and	increase	slightly	the	expression	of	TNF-α,	reversing	the	effect	of	the	other	concentrations.	
CAL-1	cells	stimulated	only	with	self-DNA	seem	to	have	basal	expression	of	all	cytokines,	similarto	
unstimulated	 CAL-1	 cells.	 In	 contrast	 to	 IFNs,	 TNF-α	mRNA	 expression	 remained	 very	 low	 for	 all	
conditions.	This	data	is	not	unexpected	given	that	Ganguly	et	al.,	2009	showed	that	pDCs	are	able	to	
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induce	IFN-α	but	not	TNF-α.	Also,	the	similarity	between	IFN-α	and	IFN-β	expression	is	not	surprising,	
since	the	same	receptor	(IFNAR1)	is	necessary	for	induction	of	both	(63,64).	Comparing	CAL-1	cells	
alone	with	the	positive	control	(CpG-A),	cells	incubated	with	CpG-A	enhance	IFN-α	and	IFN-β	mRNA	
expression,	similar	to	Steinhagen	et	al.,	2012	where	CAL-1	cells	and	primary	human	pDCs	stimulated	
with	CpG-A	showed	a	similar	behavior.	Additionally,	they	also	showed	that	CpG-A	stimulation	does	
not	induce	TNF-α	mRNA	expression,	in	agreement	with	our	results.	
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	B.	
		C.	
Figure	7	–	Expression	of	mRNA	for	IFN-α	(A),	IFN-β	(B)	and	TNF-α	(C)	was	determined	by	RT-qPCR	for	CAL-1	cells	incubated	
with	immune	complexes	prepared	with	different	LL37	concentrations	(5,	10,	20	and	50µg/ml)	and	stimulated	in	parallel	with	
CpG-A	or	with	self-DNA,	as	controls.	GAPDH	was	used	as	a	reference	gene	and	mRNA	expression	was	normalized	against	
values	obtained	for	0	h	of	incubation.	Data	are	mean	of	four	independent	experiments,	error	bars	represent	the	SEM.	
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Overall,	since	using	of	50µg/ml	of	LL37	led	to	a	decrease	on	cell	viability	of	about	50%,	the	
concentration	more	efficient	to	study	activation	of	CAL-1	cell	is	10µg/ml	of	LL37.	
To	analyze	which	concentration	of	LL37	peptide	is	best	to	induce	cytokine	production,	we	
further	 evaluated	protein	 secretion	 for	 the	 cytokines	 IFN-α,	 TNF-α	and	 IL-1β	by	ELISA	 (Figure	8).	
However,	no	secretion	of	IFN-α	and	TNF-α	was	detected.	IFN-α	absence	is	contradictory	to	our	early	
results.	These	data	are	inconsistent	with	Ganguly	et	al.,	2009	and	Steinhagen	et	al.,	2012	studies,	
where	they	show	IFN-α	and	TNF-α	secretion	upon	stimulation	for	4h	of	pDCs	with	immune	complexes	
in	primary	cells,	or	stimulation	for	3h	of	CAL-1	cells	with	CpG-A,	respectively.	Supernatants	for	6h	
incubation	were	also	tested,	although	no	secretion	was	detected.	
CAL-1	cells	stimulated	only	with	self-DNA	showed	the	highest	production	of	IL-1β.	Then,	the	
second	highest	production	of	IL-1β	is	due	to	CpG-A	stimulation,	followed	by	the	ICs	with	10µg/ml	of	
LL37.	In	addition,	all	the	other	tested	concentrations	promoted	a	lower	secretion	of	IL-1β.	
A.		 B.		 C.		
	
Figure	8	–	Protein	secretion	determined	by	ELISA	for	CAL-1	cells	incubated	with	immune	complexes	prepared	with	different	
LL37	 concentrations	 (5,	 10,	 20	 and	 50µg/ml)	 and	 stimulated	 in	 parallel	 with	 CpG-A	 and	 only	with	 self-DNA.	 A	 –	 IL-1β	
secretion;	B	–	IFN-α	secretion;	C	-	TNF-α	secretion	Data	are	mean	of	five	independent	experiments,	error	bars	represent	the	
SEM.	
	
There	are	currently	no	publications	regarding	the	induction	of	inflammasomes,	detected	by	
IL-1β	secretion,	on	CAL-1	cells	pDCs.	However,	Dombrowski	and	Schamber	et	al.,	2012	refer	that	the	
LL37	 peptide	 inhibits	 the	 AIM2	 (cytosolic	 receptor	 that	 forms	 an	 inflammasome	 after	 sensing	
cytosolic	dsDNA)	inflammasome	activation	in	keratinocytes	in	psoriasis	by	neutralizing	cytosolic	self-
DNA,	thereby	blocking	IL-1β	release.	On	Figure	8,	it	is	clear	that	CAL-1	cells	incubated	only	with	self-
nDNA	promoted	the	highest	IL-1β	secretion.	When	dsDNA	was	conjugated	with	LL37,	IL-1β	secretion	
decreased.	Thus,	our	study	also	provides	some	evidence	of	 inhibition	of	 inflammasome	on	CAL-1	
cells,	although	more	tests	are	required.	Consequently,	beyond	being	the	best	to	induce	type	I	IFNs	
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mRNA	 expression,	 the	 immune	 complexes	 of	 LL37	 with	 selfDNA	 seem	 also	 to	 modulate	 IL-1β	
secretion.	In	future	work	it	will	be	interesting	to	also	measure	IL-1β	mRNA	expression	by	RT-qPCR.	
Taken	together,	these	data	suggest	that,	the	concentration	of	LL37	promoting	CAL-1	cells	
activation,	is	10µg/ml.	However,	for	immune	complexes	no	ideal	nDNA	concentration	is	known	for	
our	cells.	
	
	
Optimizing	DNA	Concentration	for	CAL-1	stimulation	with	immune	complexes	
	
	 To	achieve	our	goal	of	analyze	stimulation	of	CAL-1	cells	with	 immune	complexes	formed	
with	self-DNA	conjugated	with	the	LL37	peptide,	there	is	a	need	to	also	optimize	the	concentration	
of	DNA	to	form	these	complexes.	Therefore,	we	started	by	testing	different	concentrations	of	DNA,	
based	on	earlier	pDC	studies.	 In	their	studies,	Lande	et	al.,	2007,	 tested	CAL-1	cells	using	DNA	at	
concentrations	of	0.1,	0.5,	2	and	10	µg/ml.	Ganguly	et	al.,	2009	showed	that	1µg/ml	is	enough	to	
promote	a	good	pDC	activation.	Here,	 some	different	concentrations	of	 self-nuclear	DNA	(nDNA)	
were	chosen	to	form	ICs	and	stimulate	CAL-1	cells:	1µg/ml,	0.5	µg/ml	and	0.2	µg/ml.		
Thus,	 mRNA	 expression	 for	 IFN-α,	 IFN-β	 and	 TNF-α	 was	 measured	 by	 RT-qPCR,	 upon	
stimulation	with	immune	complexes	prepared	with	these	different	concentrations.	Five	assays	were	
performed	upon	stimulation	for	6h	and	24h	(Table	7	and	Figure	9).	
	
	
	
Table	7	-	Relative	amount	of	IFN-α,	IFN-β	and	TNF-α	mRNA	expressed	by	CAL-1	stimulated	with	the	complexes	formed	with	
the	indicated	amount	of	nDNA,	measured	by	RT-qPCR,	after	6h	of	incubation.	
	 	 CAL-1	
alone	
nDNA	
alone	
LL37	
alone	
CpG-A	
1µg/ml	
of	nDNA	
0.5µg/ml	
of	nDNA	
0.2µg/ml	
of	nDNA	
IFN-α	
1st	test	 1	 0.8	 0	 59.743	 3.544	 0.095	 1.225	
2nd	test	 1	 9.049	 2.342	 10.31	 5.679	 7.992	 11.846	
3rd	test	 1	 2.989	 5.162	 0.531	 1.486	 2.457	 0.074	
4th	test	 1	 2.027	 0.719	 1653.929	 0.109	 0.045	 0.017	
5th	test	 1	 0.912	 0.45	 1.356	 0.372	 0.294	 1.291	
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IFN-β	
1st	test	 1	 2.185	 0	 490.053	 1.368	 0.531	 1.368	
2nd	test	 1	 9.184	 3.784	 29.281	 6.177	 14.99	 9.469	
3rd	test	 1	 0.898	 23.83	 0.34	 0.278	 0.793	 0.046	
4th	test	 1	 0.255	 3.39	 974.032	 0.015	 0.001	 0.006	
5th	test	 1	 0.87	 0.607	 1.246	 0.851	 0.585	 1.737	
TNF-α	
1st	test	 1	 1.142	 0.774	 2.016	 0.886	 0.872	 0.96	
2nd	test	 1	 1.595	 3.714	 2.965	 2.147	 2.085	 1.988	
3rd	test	 1	 1.274	 1.474	 1.002	 0.971	 1.424	 0.559	
4th	test	 1	 3.55	 0.123	 6505.287	 0.036	 0.007	 0.123	
5th	test	 1	 0	 0.863	 1.569	 1.079	 0.556	 0.965	
	
As	before,	there	was	excessive	expression	of	each	cytokine	at	the	fourth	test,	and	also	at	the	
first	test	for	IFN-β	(in	red)	(Table	7),	suggesting	some	contamination.	Excluding	these	values,	some	
variability	 remains	 visible.	 Again,	 we	 found	 no	 statistically	 significant	 differences	 but	 some	
tendencies	were	evident.	In	general,	all	the	cytokines	show	less	mRNA	than	the	positive	control,	CpG-
A	(Figure	10).	For	IFN-α,	the	immune	complexes	formed	with	0.2µg/ml	of	DNA	lead	to	higher	levels	
of	mRNA	than	the	other	concentrations.	Also	for	IFN-α,	CAL-1	cells	stimulated	only	with	self-DNA,	
show	higher	mRNA	expression	than	CAL-1	cells	alone.	For	TNF-	α,	values	remained	very	 low,	and	
CAL-1	cells	stimulated	only	with	LL37,	showed	higher	mRNA	expression	than	CAL-1	cells	alone.	 In	
theirs	studies,	Zhang	et	al.,	2008	showed	that	LL37	may	somehow	link	with	some	hypothetical	self-
DNA	extruded	from	the	cell	(108).	However,	for	cells	stimulates	only	with	self-DNA,	this	link	can	not	
be	seen	since	LL37	is	only	expressed	in	injured	cells	(48).	Overall,	the	levels	of	mRNA	obtained	upon	
stimulation	 with	 immune	 complexes	 remained	 low	 and	 there	 were	 no	 statistically	 significant	
differences	compared	with	the	control.	Thus,	despite	the	immune	complexes	formed	with	0.2µg/ml	
of	DNA	express	more	IFN-α	mRNA,	no	ideal	concentration	of	nDNA	can	be	chosen.	
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	C.		
	
	
Figure	9	-	Expression	of	mRNA	for	IFN-α	(A),	IFN-β	(B)	and	TNF-α	(C)	was	determined	by	RT-qPCR	for	CAL-1	cells	incubated	
with	immune	complexes	prepared	with	different	nDNA	concentrations	(1,	0.5	and	0.2µg/ml)	and	stimulated	in	parallel	with	
CpG-A	and	only	with	LL37	and	self-DNA.	GAPDH	was	used	as	a	reference	gene	and	mRNA	expression	was	normalized	against	
values	obtained	for	0	h	of	incubation.	Data	are	mean	of	four	independent	experiments,	error	bars	represent	the	SEM.	
	
	 In	addition	to	nDNA,	mitochondrial	DNA	(mtDNA)	might	also	be	able	to	activate	pDCs.	The	
formation	of	either	the	nDNA	or	mtDNA	complexes	are	thought	to	play	a	similar	role	in	pDC	activation	
(53).	To	test	this	fact,	an	analysis	of	the	immune	complexes	formed	by	LL37	peptide	with	mtDNA	was	
made.	However,	the	quantity	of	mtDNA	obtained	in	the	extraction	from	CAL-1	cells	was	always	very	
low,	 making	 it	 difficult	 to	 repeat	 the	 assay	 and	 optimize	 mtDNA	 concentration.	 Thus,	 some	
alternative	method	of	mtDNA	isolation	should	be	tested	to	obtain	better	results,	such	as	a	mtDNA	
isolation	kit	(53).	
	 Nevertheless,	we	evaluated	mRNA	expression	of	IFN-α,	IFN-β	and	TNF-α	by	RT-qPCR,	upon	
stimulation	 with	 immune	 complexes	 prepared	 with	 0.5µg/ml	 of	 self-mtDNA.	 Two	 assays	 were	
performed	upon	stimulation	for	6h	(Table	8	and	Figure	10).	
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Table	8	–	Relative	amount	of	IFN-α,	IFN-β	and	TNF-α	mRNA	expressed	by	CAL-1	stimulated	with	the	complexes	formed	with	
the	indicated	amount	of	mtDNA,	measured	by	RT-qPCR,	after	6h	of	incubation.	
	 	 Cells	 mtDNA	only	 LL37	only	 CpG-A	
0.5µg	of	
mtDNA	
IFN-α	
1st	test	 1	 3.286	 0	 59.743	 7332.045	
2nd	test	 1	 9.207	 0	 10.31	 7.698	
IFN-β	
1st	test	 1	 4.25	 0	 490.053	 795774.421	
2nd	test	 1	 9.388	 0	 29.281	 6.065	
TNF-α	
1st	test	 1	 0.904	 0.774	 2.016	 2123.164	
2nd	test	 1	 3.002	 0	 2.965	 3.055	
	
	 The	expression	of	cytokines	mRNA	shows	a	huge	variability.	In	general,	CAL-1	cells	stimulated	
only	with	self-mtDNA	alone,	CpG-A	and	the	immune	complexes	showed	more	mRNA	expression	than	
CAL-1	cells	alone.	Stimulation	with	LL37	alone	caused	almost	no	expression,	as	expected,	despite	
being	inconsistent	with	previous	results.	In	addition,	a	clear	effect	of	the	immune	complexes	with	
mtDNA	and	LL37	can	be	seen	on	CAL-1	cells	stimulation.	For	this	condition,	mRNA	expression	was	
higher	 for	 type	 I	 than	 for	TNF-α.	This	 is	 similar	 to	earlier	 results	 for	 LL37	and	nDNA	optimization	
assays	and	to	the	work	of	Lande	et	al.,	2007,	suggesting	that	pDCs	express	higher	levels	of	IFN-α	and	
IFN-β	 mRNA	 than	 TNF-α.	 	 Comparing	 with	 earlier	 results,	 CAL-1	 cells	 stimulation	 with	 immune	
complexes	with	LL37-mtDNA	promoted	higher	expression	of	cytokines	than	stimulation	with	LL37-
nDNA	immune	complexes.	This	is	in	agreement	with	the	work	published	by	as	Zhang	et	al.	2015	on	
pDCs,	 showing	 that	 LL37-mtDNA	 complexes	 exacerbate	 inflammation	 and	 stimulate	 IFN-α	
production,	comparing	to	LL37-nDNA	complexes	(53,54).		
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B.		
	C.		
	
Figure	10	-	Expression	of	mRNA	for	IFN-α	(A),	IFN-β	(B)	and	TNF-α	(C)	was	determined	by	RT-qPCR	for	CAL-1	cells	incubated	
with	immune	complexes	prepared	with	a	concentration	of	0.5µg/ml	of	mtDNA	and	stimulated	in	parallel	with	CpG-A	and	
only	with	LL37	and	self-mtDNA.	GAPDH	was	used	as	a	reference	gene	and	mRNA	expression	was	normalized	against	values	
obtained	for	0	h	of	incubation.	Data	are	mean	of	four	independent	experiments,	error	bars	represent	the	SEM.	
	
	
	
Finally,	secretion	of	IFN-α,	TNF-α	and	IL-1β	was	measured	by	ELISA	assays.	Five	assays	were	
performed	upon	stimulation	for	6h	and	24h	(Figure	11).	Again,	no	secretion	of	IFN-	α	and	TNF-α	was	
detected,	as	seen	earlier.	
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Figure	11	-	Secretion	of	IL-1β	determined	by	ELISA	for	CAL-1	cells	incubated	for	6h	(A)	and	24h	(B)	with	immune	complexes	
prepared	with	different	nDNA	concentrations	(1,	0.5,	0.2µg/ml)	and	mtDNA	(0.5µg/ml)	or	stimulated	in	parallel	with	CpG-
A	or	only	with	LL37	and	self-DNA,	self-mtDNA.	Data	are	mean	of	five	independent	experiments,	error	bars	represent	the	
SEM.	
	
Analyzing	the	data,	the	differences	between	the	conditions	are	very	small	and	the	error	bars	
are	huge.	Thus,	all	data	should	be	repeated	to	obtain	better	results.	
Interestingly,	no	secretion	of	cells	stimulated	with	self-mtDNA	alone	and	immune	complexes	
of	LL37-mtDNA	is	seen	in	both	time-points,	suggesting	that	mtDNA,	even	in	complex,	may	not	be	
able	 to	 induce	 the	 inflammasome	 formation.	 This	 is	 not	 shocking	 since	 AIM2	 inflammasome	
activation	is	 induced	by	detection	of	cytosolic	dsDNA	and	mtDNA,	although	being	dsDNA,	it	has	a	
circular	form,	and	may	not	be	recognized	by	AIM2.	However,	no	studies	in	this	subject	are	known.	
Analyzing	 all	 data	 acquired,	no	 robust	 answer	of	 the	best	 concentration	of	nDNA	can	be	
found.	Nevertheless,	mRNA	expression	for	 IFN-α	and	IL-1β	was	generally	higher	when	CAL-1	cells	
were	stimulated	with	immune	complexes	with	0.2µg/ml	of	nDNA,	appearing	to	be	the	best	nDNA	
concentration	to	form	immune	complexes	and	activate	CAL-1	cells.	However,	more	data	are	needed	
to	have	a	consistent	result.	Also,	the	error	bars	are,	again,	too	high,	not	being	expected	since	we	
were	working	with	a	cell	line.	Furthermore,	the	variability	between	the	assays	led	to	a	huge	standard	
deviation,	increasing	the	error	bar.	Thus,	these	assays	should	be	repeated	to	obtain	more	coherent	
data.	
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Co-localization	Analysis	by	IF	
	
After	 choosing	 the	 best	 concentrations	 of	 LL37	 peptide	 and	 self-nDNA	 to	 form	 immune	
complexes	to	activate	CAL-1	cells,	we	started	exploring	how	and	how	long	it	takes	to	the	immune	
complexes	to	enter	the	cell,	recruit	the	early	endosomes	and	trigger	the	TLR-9	signaling	pathway.	
For	that,	we	performed	an	immunocytochemistry	analysis	of	stimulated	cells,	by	staining	for	LL37,	
endosomes	and	TLR-9.	We	first	compared	the	control	conditions	(CAL-1	cells	alone,	CAL-1	stimulated	
with	CpG-A,	CAL-1	stimulated	with	LL37	alone	and	CAL-1	stimulated	with	DNA	alone)	to	understand	
whether	CAL-1	 cells	 activation	may	affect	 expression	of	 TLR-9	and	 induction	of	 early	 endosomes	
(EEA1)	 (Figure	 12).	 	 LL37	 peptide	 was	 stained	 with	 Mouse	 anti-LL37-Alexa-Fluor-488,	 the	 early	
endosomes,	 stained	 with	 Rabbit	 anti-EEA1	 with	 the	 secondary	 Alexa-Fluor-647	 and	 the	 TLR-9	
receptor	 stained	 with	 Mouse	 anti-TLR-9	 with	 the	 secondary	 Alexa-Fluor-568.	 One	 assay	 was	
performed	for	each	time-point.	
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Figure	12	–	Immunofluorescence	microscopy	analysis	showing	the	staining	of,	TLR-9,	early	endosomes	(EEA1)	and	LL37	in	
the	control	conditions:	CAL-1	cells	alone,	CAL-1	cells	stimulated	with	CpG-A,	CAL-1	cells	stimulated	only	with	LL37	and	CAL-
1	cells	stimulated	only	with	self-nDNA,	at	120minutes	of	incubation.	Scale	bars	=	4µm.	Images	are	representative	of	CAL-1	
cells,	in	mean	9	cells	per	condition.	
	
As	expected,	CAL-1	cells	alone	and	CAL-1	stimulated	with	CpG-A	or	with	DNA	alone	did	not	
stain	for	LL37,	thus	confirming	that	the	LL37	peptide	is	not	expressed	on	normal	conditions,	as	stated	
by	Lande	et	al.,	2007.	Early	endosomes	were	present	 in	all	conditions,	although	some	differences	
were	visible:	first,	for	CAL-1	cells	alone	staining	was	lower	that	for	all	the	remaining	conditions,	and	
second,	early	endosomes	are	surrounding	the	cells	near	the	membrane	in	all	conditions,	expect	for	
those	that	contain	LL37	peptide,	where	a	round	shape	staining	was	visible	near	one	side	of	the	cell.	
TLR-9	triggering	seemed	to	enhance	upon	activation	by	CpG-A,	as	in	Combes	et	al.,	2017,	and	with	
ICs,	and	also	surprisingly	by	cells	stimulated	with	only	self-DNA.		
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We	next	proceeded	 to	perform	a	 co-localization	analysis	of	 ICs	with	either	TLR9	or	EEA1	
(early	endosome	marker),	at	different	time-points	(15,	30,	60	and	120minutes).	Data	were	compared	
to	the	same	conditions	with	0h	of	incubation	(Figure	13).	
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Figure	13	–	Immunofluorescence	microscopy	analysis	to	detect	the	presence	of	the	immune	complexes	with	LL37	staining	
and	the	recruitment	of	TLR-9	and	the	early	endosomes	(EEA1)	by	the	immune	complexes,	at	different	time	points	(15,	30,	
60	and	120minutes).	Non-treated	condition	(0h)	was	used	as	a	reference.	Scale	bars	=	4µm.	Images	are	representative	of	
CAL-1	cells,	in	mean	9	cells	per	condition.	
	
It	was	 found	 that	 LL37	peptide	 of	 the	 immune	 complexes	was	 surrounding	 the	 cell	 until	
60minutes	of	incubation	while	at	120min	of	incubation,	little	spots	of	LL37	could	be	seen	inside	the	
cell.	This	raises	the	possibility	that	the	immune	complexes	take	between	60-120minutes	to	enter	the	
cell.	On	the	other	hand,	early	endosomes	recruitment	does	not	seem	to	start	at	the	same	time-point.	
Observing	EEA1	staining,	the	role	of	early	endosomes	in	this	pathway	seems	to	start	60minutes	after	
the	incubation	with	the	immune	complexes.	TLR-9	was	located	near	the	early	endosomes	and	co-
localized	with	the	peptide	only	after	60minutes	of	incubation	with	ICs.	
	 Co-localization	 of	 the	 LL37	 of	 the	 immune	 complexes	 with	 both	 EEA1	 and	 TLR-9	 was	
determined	by	measuring	the	Pearson’s	Coefficient	for	each	cell	in	test,	using	the	plugin	JACoP,	of	
ImageJ	software,	in	each	time-point	(Figure	14).	
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A.		
B.		
	
Figure	14	–	Co-localization	analysis	expressed	by	Pearson’s	Coefficient	for	LL37	and	TLR-9	(A)	and	for	LL37	and	EEA1	(B),	at	
different	time-points	(15,	30,	60	and	120	minutes).	Data	are	representative	of	each	cell	(12<n<20)	in	each	condition	obtained	
by	Immunofluorescence	and	Pearson’s	Coefficient	was	measured	by	JACoP	plugin	of	ImageJ.	Error	bars	represent	the	SEM	
and	the	middle	bar	represents	the	mean.	
	
	 In	general,	a	heterogeneous	population	of	cells	is	seen,	showing	different	behaviors	within	
the	 same	 condition.	 For	 LL37	 and	 TLR-9,	 the	 best	 correlation	 is	 clear	 between	 30-60minutes	 of	
incubation	with	the	complexes.	However,	the	cell	population	is	more	homogeneous	after	60minutes	
of	incubation,	being	similar	to	the	results	on	Figure	13.	
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For	LL37	and	EEA1,	the	best	correlation	is	saw	between	15-30minutes	of	 incubation,	thus	
suggesting	 that	 early	 endosomal	 recruitment	 begins	 after	 15minutes	 of	 incubation	 with	 ICs.	
However,	 for	 15minutes,	 the	 cell	 population	 is	 extremely	 heterogeneous,	 being	more	 consistent	
between	 30-60minutes	 of	 incubation.	 Also,	 TLR-9	 need	 to	 be	 translocated	 to	 the	 endosomal	
compartment	 and	 during	 this	 translocation,	 they	 can	 co-localize	 with	 the	 immune	 complexes	
surrounding	the	cell,	enhancing	the	coefficient	wrongly.	
Taken	together,	these	data	suggest	that	the	internalization	of	the	immune	complexes	occurs	
between	30-60minutes,	recruiting	early	endosomes	and	triggering	TLR-9	signaling.	As	stated	earlier,	
upon	120minutes	the	coefficient	decreases	for	both	conditions	(Figure	14),	suggesting	that	2h	after	
adding	 the	 complexes,	 these	 have	 been	 processed	 and	 no	 longer	 remain	 associated	 with	 early	
endosomes	nor	TLR-9.	Combes	et	al.,	2017	showed	that	CAL-1	cells	and	pDCs	promote	TLR-9	and	
early	endosomal	recruitment	upon	1h	of	stimulation,	although	the	marker	for	endosomes	was	BAD-
LAMP	 and	 stimulation	 performed	 with	 CpG-A.	 Interestingly,	 the	 coefficients	 decreases	 in	 both	
conditions	(co-localization	of	LL37	with	TLR-9	or	EEA1)	upon	120minutes	of	stimulation.	This	is	not	
surprising	since	Combes	et	al.,	2017	found	that	endosomal	and	TLR-9	recruitment	decreased	2h	upon	
stimulation.	
Here,	our	results	suggest	that	immune	complexes	trigger	TLR-9	and	early	endosomes	upon	
30-60minutes	 of	 stimulation.	 After	 stimulation	 of	 2h,	 ICs	 seemed	 to	 be	 excluded	 from	 early	
endosomes,	decreasing	the	TLR-9	signaling.	However,	the	data	need	to	be	repeated	to	obtain	more	
information	to	answer	this	question.	
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IV. Conclusions	
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Conclusion	
	
In	this	thesis,	we	showed	that	CAL-1	cells	can	be	activated	with	immune	complexes	of	self-
DNA,	which	results	on	a	type	I	IFN	response.	LL37,	an	antimicrobial	peptide,	could	associate	with	self-
nDNA,	 as	 well	 as	 with	 self-mtDNA,	 forming	 immune	 complexes	 that	 activate	 innate	 immune	
responses,	 thus	 breaking	 innate	 tolerance	 to	 self-DNA.	 This	 activation	 with	 immune	 complexes	
triggered	the	transcription	of	IFN-α	and	IFN-β	mRNA,	but	not	TNF-α	in	CAL-1	cells,	as	reported	for	
primary	 pDCs.	 Preliminary	 data	 also	 indicates	 that	 activated	 CAL-1	 cells	 can	 secrete	 IL-1β	 upon	
stimulation	with	immune	complexes	with	self-nDNA,	but	not	self-mtDNA,	suggesting	a	role	of	nDNA-
LL37	complexes	in	induction	of	the	inflammasome	in	pDC.	Our	findings	revealed	that	these	immune	
complexes	 may	 induce	 activation	 of	 these	 cells	 through	 TLR-9	 signaling	 and	 early	 endosomes	
recruitment.		
Based	on	our	work,	future	studies	may	be	performed	to	show	more	insights	about	immune	
complexes	 formation,	 how	 they	 trigger	 TLR-9	 signaling	 and	 how	 CAL-1	 cells	 are	 related	 to	
inflammasome	induction.		
These	findings	contribute	to	establish	CAL-1	cells	as	a	pDC	model	that	may	possibly	help	to	
understand	pDCs	in	the	future.	
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